CN114364676B - 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用 - Google Patents
新型三环芳香杂环化合物,及其制备方法、药物组合物和应用 Download PDFInfo
- Publication number
- CN114364676B CN114364676B CN202080063269.8A CN202080063269A CN114364676B CN 114364676 B CN114364676 B CN 114364676B CN 202080063269 A CN202080063269 A CN 202080063269A CN 114364676 B CN114364676 B CN 114364676B
- Authority
- CN
- China
- Prior art keywords
- group
- substituted
- unsubstituted
- cancer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 125000006615 aromatic heterocyclic group Chemical group 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 165
- 108010074708 B7-H1 Antigen Proteins 0.000 claims abstract description 30
- 102000008096 B7-H1 Antigen Human genes 0.000 claims abstract description 30
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims description 101
- -1 nitro, hydroxy Chemical group 0.000 claims description 60
- 239000002994 raw material Substances 0.000 claims description 53
- 125000005842 heteroatom Chemical group 0.000 claims description 42
- 229910052757 nitrogen Inorganic materials 0.000 claims description 38
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 36
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 34
- 230000015572 biosynthetic process Effects 0.000 claims description 32
- 238000003786 synthesis reaction Methods 0.000 claims description 32
- 239000000543 intermediate Substances 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 229910052760 oxygen Inorganic materials 0.000 claims description 26
- 229910052717 sulfur Inorganic materials 0.000 claims description 26
- 125000001424 substituent group Chemical group 0.000 claims description 22
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 17
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 239000003054 catalyst Substances 0.000 claims description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 11
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 11
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 11
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 238000005859 coupling reaction Methods 0.000 claims description 11
- 229910052805 deuterium Inorganic materials 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 11
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 claims description 5
- 208000035473 Communicable disease Diseases 0.000 claims description 5
- 229910052796 boron Inorganic materials 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 150000003950 cyclic amides Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000006722 reduction reaction Methods 0.000 claims description 4
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 claims description 4
- 208000018359 Systemic autoimmune disease Diseases 0.000 claims description 3
- 229960003852 atezolizumab Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 239000002841 Lewis acid Substances 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 238000005658 halogenation reaction Methods 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 150000007517 lewis acids Chemical class 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 206010061311 nervous system neoplasm Diseases 0.000 claims description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 208000028466 reproductive system neoplasm Diseases 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 208000029584 urinary system neoplasm Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 241000764238 Isis Species 0.000 claims 1
- 230000018044 dehydration Effects 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- 150000003951 lactams Chemical class 0.000 claims 1
- 230000001546 nitrifying effect Effects 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000012453 solvate Substances 0.000 abstract description 14
- 230000003287 optical effect Effects 0.000 abstract description 3
- 230000019491 signal transduction Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 description 106
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 49
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- 238000004809 thin layer chromatography Methods 0.000 description 40
- 239000000243 solution Substances 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 29
- 239000000047 product Substances 0.000 description 29
- 239000000203 mixture Substances 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 238000001035 drying Methods 0.000 description 17
- 239000007858 starting material Substances 0.000 description 17
- 238000010189 synthetic method Methods 0.000 description 17
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 13
- 238000001308 synthesis method Methods 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 11
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 125000001072 heteroaryl group Chemical group 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000005549 heteroarylene group Chemical group 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QPMSJEFZULFYTB-PGMHMLKASA-N (3r)-pyrrolidin-3-ol;hydrochloride Chemical compound Cl.O[C@@H]1CCNC1 QPMSJEFZULFYTB-PGMHMLKASA-N 0.000 description 2
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 101001091423 Agaricus bisporus Polyphenol oxidase 2 Proteins 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 2
- 101000705994 Bombyx mori Phenoloxidase subunit 2 Proteins 0.000 description 2
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 101000606124 Margaritifera margaritifera Tyrosinase-like protein 2 Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 description 2
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 101000773106 Pinctada maxima Tyrosinase-like protein Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910001413 alkali metal ion Inorganic materials 0.000 description 2
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000000732 arylene group Chemical group 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- KQEVIFKPZOGBMZ-UHFFFAOYSA-N methyl 3-bromopropanoate Chemical compound COC(=O)CCBr KQEVIFKPZOGBMZ-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 1
- 125000006584 (C3-C10) heterocycloalkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- HXRVTZVVSGPFEC-BTJKTKAUSA-N (z)-but-2-enedioic acid;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)C(O)C(O)C(O)=O HXRVTZVVSGPFEC-BTJKTKAUSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IILVSKMKMOJHMA-UHFFFAOYSA-N 3-bromo-2-methylaniline Chemical compound CC1=C(N)C=CC=C1Br IILVSKMKMOJHMA-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 101001091417 Agaricus bisporus Polyphenol oxidase 1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 101001125487 Bombyx mori Phenoloxidase subunit 1 Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical compound [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 101000606125 Margaritifera margaritifera Tyrosinase-like protein 1 Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029132 Nephritis haemorrhagic Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000012269 PD-1/PD-L1 inhibitor Substances 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- WMSPXQIQBQAWLL-UHFFFAOYSA-N cyclopropanesulfonamide Chemical compound NS(=O)(=O)C1CC1 WMSPXQIQBQAWLL-UHFFFAOYSA-N 0.000 description 1
- 108010021848 cyclosomatostatin Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- HHRKFGMMAHZWIM-UHFFFAOYSA-N ethenoxyboronic acid Chemical compound OB(O)OC=C HHRKFGMMAHZWIM-UHFFFAOYSA-N 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910001416 lithium ion Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- UOCWTLBPYROHEF-UHFFFAOYSA-N methyl azetidine-3-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1CNC1 UOCWTLBPYROHEF-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000000802 nitrating effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940121653 pd-1/pd-l1 inhibitor Drugs 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011110 re-filtration Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明提供了一种新型三环芳香杂环化合物,及其制备方法、药物组合物和应用,具体地,本发明提供了一种如下式I所示的化合物,或其光学异构体、水合物、溶剂合物,或其药学上可接受的盐;其中,各基团的定义如说明书中所述。所述的式I化合物可以用于治疗与PD‑1/PD‑L1信号通路有关的疾病。
Description
技术领域
本发明涉及小分子药物领域,具体地,本发明提供了一种可以用于治疗与PD-1/PD-L1信号通路有关的疾病的小分子化合物。
发明背景
免疫系统对控制及根治很多疾病起着至关重要的作用,像各种癌症、病毒引起的疾病等。但癌症细胞经常能通过一些途径躲避或抑制免疫系统,从而快速繁殖。其中一个方式就是改变免疫细胞上表达的激活和抑制分子。阻断抑制免疫检查点,像PD-1,证明是一个非常有效的抑制癌细胞的方法。
PD-1是程序性细胞死亡蛋白-1,也称之为CD279。它主要在激活的T细胞和B细胞中表达,功能是抑制细胞的激活,这是免疫系统的一种正常的自稳机制,因为过度的T/B细胞激活会引起自身免疫病,所以PD-1是我们人体的一道保护墙。PD-1是由268个氨基酸组成的I型跨膜糖蛋白,它的结构主要包括外免疫球蛋白可变区、疏水跨膜区以及胞内区。胞内区包含两个磷酸化位点,分别位于免疫受体酷氨酸抑制基序和免疫受体酷氨酸转换基序,这也证明PD-1能够反向调节T细胞受体介导的信号。PD-1有两个配体,PD-L1和PD-L2,它们在表达方式上不同。PD-L1在多种肿瘤细胞中均有上调表达,它与T细胞上的PD-1结合,抑制T细胞增殖和活化,使T细胞处于失活状态,最终诱导免疫逃逸。
PD-1/PD-L1发挥着反向免疫调节作用。当PD-1与PD-L1结合后,可致使T细胞的免疫受体酷氨酸转换基序结构域的酪氨酸多磷酸化,磷酸化的酪氨酸可结合磷酸酶蛋白酪氨酸酶2和蛋白酪氨酸酶1。这样即可阻碍细胞外信号调节激酶的活化,还可阻断磷脂肌醇3-激酶(PI3K)和丝氨酸-苏氨蛋白激酶(Akt)的激活,从而抑制T淋巴细胞增殖和相关细胞因子的分沁。PD-1/PD-L1信号抑制T细胞活化和增殖的同时,还可使细胞因子白细胞介素2、干扰素γ和IL-10的分泌。此外,PD-1/PD-L1信号对B细胞也有类似的免疫功能,当PD-1与B细胞抗原受体结合后,PD-1细胞质区与含有蛋白酪氨酸酶2结合位点的酪氨酸酶发生作用,从而阻碍B细胞的活化。
基于PD-1/PD-L1的免疫疗法是新一代备受关注的免疫疗法。最近几年,一系列令人惊喜的研究结果证实PD-1/PD-L1抑制剂对多种肿瘤具有强大的抗肿瘤活性。目前已经上市的PD-1/PD-L1抗体调节剂有BMS的Ninolumab、Merck的Lambrolizumab以及Roche的Atezolizumab。除此之外还有很多在研的PD-1/PD-L1抗体调节剂,包括Cure Tech的Pidilizumab、GSK的AMP-224和AstraZeneca的MEDI-4736。
虽然肿瘤免疫治疗被认为是靶向治疗后癌症治疗的新一代革命。但是目前上市和在研的PD-1单抗药有其自身的缺陷,包括只能注射给药,不能口服,在体内不稳定,易被蛋白酶分解,易产生免疫交叉反应,纯化比较困难且生产成本高等。所以PD-1/PD-L1相互作用的小分子调节剂是肿瘤免疫治疗的更好选择。
综上所述,本领域迫切需要开发新型PD-1/PD-L1相互作用的小分子调节剂。
发明内容
本发明的目的是提供一种新型PD-1/PD-L1相互作用的小分子调节剂。
本发明的第一方面,一种如下式I所示的化合物,或其光学异构体、水合物、溶剂合物,或其药学上可接受的盐:
其中,n为0、1、2、3、4或5;
m、p、q和t,v,u各自独立地选自0、1、2、3,4;
X1、X2、X3、X4、X5和X6各自独立地选自下组:N、O、S、SO、SO2、C(R)2、CHR、NR;
Y1、Y2、Y3、Y4、Y5和Y6各自独立地选自下组:N、CH、C;
其中,X3、X4、X5、X7、X8、X9的碳原子上的氢(如存在的情况下)均可各自独立的被氘替换;
各自独立地选自下组:取代或未取代的C6-C10亚芳基、或取代或未取代的具有1-3个杂原子的5-12元(优选5-7元)亚杂芳基、取代或未取代的5-12元亚杂环基、取代或未取代的5-12元的C3-C12(优选为C5-C12)亚环烷基;
选自下组:取代或未取代的5-12元杂芳基、取代或未取代的C6-C10芳基、取代或未取代的5-12元杂环基、取代或未取代的5-12元的C3-C12(优选为C5-C12)环基,其中,所述的杂环基具有1-3个杂原子;
L1选自下组:化学键、取代或未取代的C1-C4亚烷基、取代或未取代的C2-C4亚烯基、取代或未取代的C2-C4亚炔基、-S-、-O-、取代或未取代的-NH-、-S(O)-、-S(O)2-、取代或未取代的-NHC(O)NH-、取代或未取代的/>取代或未取代的/>取代或未取代的/>
且表示单键或双键;
R、R1、R2、R3、R4和R5各自独立地选自下组:H、-CN、三氟甲基、-CHF2、-OCF3、-OCHF2、磺酰氨基、硝基、羟基、卤素、-S-R8、-S(O)-R8、-S(O)2-R8、取代或未取代的C1-C10烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C1-C6烷氧基、取代或未取代的C3-C8环烷基、氧代(即=O)、=NRf、-CN、羟基(此处两个取代基建议保留)、NRdRe(例如氨基)、取代或未取代的C1-C6胺基、取代或未取代的-(C1-C6亚烷基)-NH-(C1-C6亚烷基)、羧基、取代或未取代的C6-C10芳基、取代或未取代的具有1-3个杂原子的5-12元杂芳基、取代或未取代的具有1-4个杂原子的3-12元杂环基,其中,取代或未取代的C1-C10烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C1-C6烷氧基、取代或未取代的C3-C8环烷基、氧代(即=O)、=NRf、羟基、NRdRe(例如氨基)、取代或未取代的C1-C6胺基、取代或未取代的-(C1-C6亚烷基)-NH-(C1-C6亚烷基)、羧基、取代或未取代的C6-C10芳基、取代或未取代的具有1-3个杂原子的5-12元杂芳基、取代或未取代的具有1-4个杂原子的3-12元杂环基的碳原子上的氢均可各自独立的被氘去掉;取代或未取代的取代或未取代的/>取代或未取代的/> (请修改此处结构式)改动、/>其中,Rb和Rc各自独立地选自下组:H、取代或取代的C1-C8烷基;或所述的Rb和Rc与相邻的N原子共同构成取代或未取代的具有1-3个选自N、S和O的杂原子的3-10元杂环基,或所述的Rb和Rc与相邻的N原子共同构成取代或未取代的4-10元环,所述取代基包括但不限于:羟基、羧基、巯基、氨基、F、C,其中,Rb、Rc和Rd的碳原子上的氢均可各自独立地被氘替换;或-(L1a)r-(L2a)s-(L3a)s-;-C0-8-O-R8,-C0-8-C(O)OR8,-C0-8-OC(O)OR8,-C0-8-NR8R9,-C0-8-N(R8)C(O)R9,-C0-8-C(O)NR8R9;
R8和R9各自独立地选自下组:H、羟基,取代或未取代的C1-C10烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C1-C6烷氧、取代或未取代的C3-C8环烷基、氧代(即=O)、=NRf、-CN、羟基、NRdRe(例如氨基)、取代或未取代的C1-C6胺基、取代或未取代的-(C1-C6亚烷基)-NH-(C1-C6亚烷基)、羧基、取代或未取代的C6-C10芳基、取代或未取代的具有1-3个杂原子的5-12元杂芳基、取代或未取代的具有1-4个杂原子的3-12元杂环基,取代或未取代的取代或未取代的/>取代或未取代的或-(L1a)r-(L2a)s-(L3a)s-;
各个L1a各自独立地为选自下组的基团;化学键、取代或未取代的C1-C7亚烷基、取代或未取代的C2-C4亚烯基、取代或未取代的C2-C4亚炔基、-S-、-O-、取代或未取代的-NH-、-S(O)-、或-S(O)2-;
L2a选自下组:取代或未取代的C6-C12亚芳基、取代或未取代的具有1-3个杂原子的5-12元亚杂芳基、取代或未取代的C3-C8亚环烷基、取代或未取代的具有1-3个杂原子的3-10元亚杂环基;
L3a选自下组:取代或未取代的C1-C10烷基、C1-C10芳基、-CN、羟基、氨基、羧基、-CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、-ORg、-N(Rg)2-CO2Rg、-CON(Rg)2、-CONHCORg、NRg-CO-N(Rg)2、-NRg-SO2-N(Rg)2;
r为1、2、3、4、5、6;
s分别为0、1、2;
Rd、Re和Rg各自独立地选自下组:H、取代或未取代的C1-C6烷基、取代或未取代的C3-C10环烷基、取代或未取代的C6-C10芳基;或Rd和Re共同形成取代或未取代的具有1-3个选自N、S和O的杂原子的4-10(优选为5-10)元杂环基;
所述的Rf选自下组:H、取代或未取代的C1-C6烷基、取代或未取代的C6-C10芳基、取代或未取代的5-10元杂芳基、氰基、-C(=O)-NRdRe、-C(=O)-取代或未取代的C1-C6烷氧基、-C(=O)-取代或未取代的C1-C6烷基、-C(=O)-取代或未取代的C3-C10环烷基、-C(=O)-取代或未取代的C2-C6烯基、-C(=O)-取代或未取代的C2-C6炔基;
除非特别说明,所述的“取代”是指被选自下组的一个或多个(例如2个、3个、4个等)取代基所取代:卤素(包括-F、-Cl、-Br、-I)、-CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3、氧代(=O)、-CN、羟基、氨基、C1-C6烷胺基、羧基、-NHAc、 未取代或被一个或多个取代基取代的选自下组的基团:C1-C6烷基、C1-C6烷氧基、C6-C10芳基、C3-C8环烷基、卤代的C6-C10芳基、具有1-3个选自N、S和O的杂原子的5-10元杂芳基、具有1-3个选自N、S和O的杂原子的5-10元杂环基;所述的取代基选自下组:卤素、羟基、羧基、氧基、氰基、C1-C6烷氧基、C1-C6烷胺基;
上述各式中,任一所述杂原子选自下组:B、P、N、S和O。
在另一优选例中,当A和L1均为无时,B为选自下组的基团:取代或未取代的C6-C10芳基、或取代或未取代的具有1-3个杂原子的5-12元(优选5-7元)杂芳基、取代或未取代的5-12元杂环基、取代或未取代的5-12元的C3-C12(优选为C5-C12)环烷基。
在另一优选例中,所述的式I化合物具有如下式所示的结构:
在另一优选例中,本发明提供了一种如下式I所示的化合物,或其光学异构体、水合物、溶剂合物,或其药学上可接受的盐:
其中,n为0、1、2或3;
m、p、q和t各自独立地选自0、1、2、3或4;
X1,X2,X3,X4,X5和X6各自独立地选自下组:N、O、S、SO、SO2、C(R)2、NR;
Y1,Y2,Y3,Y4,Y5和Y6各自独立地选自下组:N、CH、C;
各自独立地选自下组:取代或未取代的C6-C10亚芳基、或取代或未取代的具有1-3个杂原子的5-12元(优选5-7元)亚杂芳基、取代或未取代的5-12元亚杂环基、取代或未取代的5-12元的C5-C12亚环烷基;
选自下组:取代或未取代的5-12元杂芳基、取代或未取代的C6-C10芳基、取代或未取代的5-12元杂环基、取代或未取代的5-12元的C5-C12环基,其中,所述的杂环基具有1-3个杂原子;
L1选自下组:化学键、取代或未取代的C1-C4亚烷基、取代或未取代的C2-C4亚烯基、取代或未取代的C2-C4亚炔基、-S-、-O-、取代或未取代的-NH-、-S(O)-、-S(O)2-、取代或未取代的-NHC(O)NH-、取代或未取代的/>取代或未取代的/>取代或未取代的/>
R、R1、R2、R3、R4和R5各自独立地选自下组:H、-CN、三氟甲基、磺酰氨基、硝基、羟基、卤素、-S-R8、-S(O)-R8、-S(O)2-R8、取代或未取代的C1-C10烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C1-C6烷氧基、取代或未取代的C3-C8环烷基、氧代(即=O)、=NRf、-CN、羟基、NRdRe(例如氨基)、取代或未取代的C1-C6胺基、取代或未取代的-(C1-C6亚烷基)-NH-(C1-C6烷基)、羧基、取代或未取代的C6-C10芳基、取代或未取代的具有1-3个杂原子的5-12元杂芳基、取代或未取代的具有1-4个杂原子的3-12元杂环基,取代或未取代的取代或未取代的/>或-(L1a)r-(L2a)s-(L3a)s-;-C0-8-O-R8,-C0-8-C(O)OR8,-C0-8-OC(O)OR8,-C0-8-NR8R9,-C0-8-N(R8)C(O)R9,-C0-8-C(O)NR8R9;
R8和R9各自独立地选自下组:H、羟基,取代或未取代的C1-C10烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C1-C6烷氧基、取代或未取代的C3-C8环烷基、氧代(即=O)、=NRf、-CN、羟基、NRdRe(例如氨基)、取代或未取代的C1-C6胺基、取代或未取代的-(C1-C6亚烷基)-NH-(C1-C6亚烷基)、羧基、取代或未取代的C6-C10芳基、取代或未取代的具有1-3个杂原子的5-12元杂芳基、取代或未取代的具有1-4个杂原子的3-12元杂环基,取代或未取代的取代或未取代的/>或-(L1a)r-(L2a)s-(L3a)s-;
各个L1a各自独立地为选自下组的基团;化学键、取代或未取代的C1-C7亚烷基、取代或未取代的C2-C4亚烯基、取代或未取代的C2-C4亚炔基、-S-、-O-、取代或未取代的-NH-、-S(O)-、或-S(O)2-;
L2a选自下组:取代或未取代的C6-C12亚芳基、取代或未取代的具有1-3个杂原子的5-12元亚杂芳基、取代或未取代的C3-C8亚环烷基、取代或未取代的具有1-3个杂原子的5-10元亚杂环基;
L3a选自下组:取代或未取代的C1-C10烷基、C1-C10芳基、-CN、羟基、氨基、羧基、-CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg;
r为1、2、3、4、5、6;
s分别为0、1、2;
Rd、Re和Rg各自独立地选自下组:H、取代或未取代的C1-C6烷基、取代或未取代的C3-C10环烷基、取代或未取代的C6-C10芳基;或Rd和Re共同形成取代或未取代的具有1-3个选自N、S和O的杂原子的5-10元杂环基;
所述的Rf选自下组:H、取代或未取代的C1-C6烷基、取代或未取代的C6-C10芳基、取代或未取代的C6-C10杂芳基、氰基、-C(=O)-NRdRe、-C(=O)-取代或未取代的C1-C6烷氧基、-C(=O)-取代或未取代的C1-C6烷基、-C(=O)-取代或未取代的C3-C10环烷基、-C(=O)-取代或未取代的C2-C6烯基、-C(=O)-取代或未取代的C2-C6炔基;
除非特别说明,所述的“取代”是指被选自下组的一个或多个(例如2个、3个、4个等)取代基所取代:卤素:包括但不限于-F、Cl、Br、-CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3、氧代、-CN、羟基、氨基、C1-C6烷胺基、羧基、-NHAc、未取代或被一个或多个选自下组的取代基取代的选自下组的基团:C1-C6烷基、C1-C6烷氧基、C6-C10芳基、C3-C8环烷基、卤代的C6-C10芳基、具有1-3个选自N、S和O的杂原子的5-10元杂芳基、具有1-3个选自N、S和O的杂原子的5-10元杂环基;所述的取代基选自下组:卤素、羟基、羧基、氰基、C1-C6烷氧基、C1-C6烷胺基;
上述各式中,任一所述杂原子选自下组:B、P、N、S和O。
在另一优选例中,所述的各自独立地为选自下组的环形成的二价基团:/> 其中,所述的环的成键位置可以为N或C(环上的取代基未示出)。
在另一优选例中,所述的R2和R3各自独立地选自下组:甲基、-F、Cl、Br、-CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3、-CN、羟基、氨基。
在另一优选例中,所述的的成键位置可以是o、p、m位
在另一优选例中,所述的的在一个成键位置处,一个与N或C相连的H被键所取代。
在另一优选例中,所述的为如下所示的结构:
在另一优选例中,所述的具有如下式所示的结构:
其中,
X6、X7、X8、X9、X10和X11各自独立地选自下组:N、CR;
R6选自下组:H、卤素、取代或未取代的C1-C6烷基、取代或未取代的C2-C6烯基、取代或未取代的C2-C6炔基、取代或未取代的C1-C6烷氧基、取代或未取代的C3-C8环烷基、氧代(即=O)、=NRf、-CN、羟基、NRdRe(例如氨基)、取代或未取代的C1-C6胺基、取代或未取代的-(C1-C6亚烷基)-NH-(C1-C6亚烷基)、羧基、取代或未取代的C6-C10芳基、取代或未取代的具有1-3个杂原子的5-12元杂芳基、取代或未取代的具有1-4个杂原子的5-12元杂环基,取代或未取代的取代或未取代的/>取代或未取代的/>或-(L1a)r-(L2a)s-(L3a)s-,-C0-8-O-R8,-C0-8-C(O)OR8,-C0-8-OC(O)OR8,-C0-8-NR8R9,-C0-8-N(R8)C(O)R9,-C0-8-C(O)NR8R9。
在另一优选例中,所述的具有如下式所示的结构:/> 其中,所述的环的成键位置可以为N或C(环上的取代基未示出)。
在另一优选例中,所述的R6为R1;或为其中,Rb和Rc各自独立地选自下组:H、取代或未取代的C1-C8烷基;或所述的Rb和Rc与相邻的N原子共同构成取代或未取代的具有1-3个选自N、S和O的杂原子的3-10元杂环基。
在另一优选例中,所述的环具有如下式IV所示的取代基:
其中,w为0,1,2,3,4,5,6;
所述的各个L4独立地选自下组:取代或未取代的C1-C4亚烷基、-S-、-O-、NRf、-S(O)-、-S(O)2-;优选为取代或未取代的C1-C4亚烷基,其中,取代或未取代的C1-C4亚烷基上碳原子上的氢均可各自独立地被氘替换;前提条件是各个L4共同形成的结构是化学稳定的;
选自下组:取代或未取代的C3-C10环烷基、取代或未取代的具有1-3个选自B、P、N、S和O的杂原子的3-10元杂环基;优选地,所述的/>为或取代或未取代的3-8元含氮杂环基,或取代或未取代的4-10元环酰胺,其中,3-8元含氮杂环基取代或未取代的4-10元环酰胺基的成环碳原子上的氢均可各自独立被氘替换;
各个R7各自独立地选自下组:取代或未取代的C1-C6烷基、-CN、羟基、氨基、羧基、-ORg、-N(Rg)2、-CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、-CO2Rg、-CON(Rg)2、CONHCORg、NRg-CO-N(Rg)2、-NRg-SO2-N(Rg)2;Rf和Rg的定义如前所述,其中Rf和Rg的碳原子上的氢均可各自独立地被氘替换,其中,所述的取代基选自下组:卤素、羟基、羧基、氰基、C1-C6烷氧基。
在另一优选例中,至少一个R4为选自下组的基团:NRdRe;所述的Rd和Re各自独立地选自下组:H、取代或未取代的C1-C6烷基、取代或未取代的C3-C10环烷基、-C0-8-O-R8、-C0-8-C(O)OR8、-C0-8-OC(O)OR8、-C0-8-NR8R9、-C0-8-N(R8)C(O)R9、-C0-8-C(O)NR8R9、取代或未取代的C6-C10芳基;或Rd和Re共同形成取代或未取代的3-10元环烷基,或具有1-3个选自N、S和O的取代或未取代的杂原子的3-10元杂环基。在另一优选例中,此处所述的取代基为羧基、羟基、R10为取代或未取代的C1-C6烷基、取代或未取代的C3-C10环烷基,优选地,R10为甲基、异丙基、环丙基和1-甲基环丙基,其中Rd、Re和R10的碳原子上的氢均可各自独立被氘替换。
在另一优选例中,所述的环具有如下式IV所示的取代基:
其中,所述的各个L4独立地选自下组:取代或未取代的C1-C4亚烷基、-S-、-O-、-NRa-、-NRf、-S(O)-、-S(O)2-;优选为取代或未取代的C1-C4亚烷基,前提条件是各个L4共同形成的结构是化学稳定的;
选自下组:取代或未取代的C5-C10环烷基、取代或未取代的具有1-3个选自B、P、N、S和O的杂原子的3-10元杂环基;优选地,所述的/>为3-8元含氮杂环基;
各个R7各自独立地选自下组:取代或未取代的C1-C6烷基、-CN、羟基、氨基、羧基、-ORg、-N(Rg)2、-CO-NH-SO2-Rg、-NH-SO2-Rg、-SO2-NH-CO-Rg、-CO2Rg、-CON(Rg)2、CONHCORg、NRg-CO-N(Rg)2、-NRg-SO2-N(Rg)2;其中,所述的取代基选自下组:卤素、羟基、羧基、氰基、C1-C6烷氧基。
在另一优选例中,至少一个R4为选自下组的基团:NRdRe;所述的Rd和Re各自独立地选自下组:H、取代或未取代的C1-C6烷基、取代或未取代的C3-C10环烷基、-C0-8-O-R8、-C0-8-C(O)OR8、-C0-8-OC(O)OR8、-C0-8-NR8R9、-C0-8-N(R8)C(O)R9、-C0-8-C(O)NR8R9、取代或未取代的C6-C10芳基;或Rd和Re共同形成取代或未取代的3-10元环烷基,或具有1-3个选自N、S和O的取代或未取代的杂原子的3-10元杂环基。在另一优选例中,此处所述的取代基为羧基、羟基、R10为取代或未取代的C1-C6烷基、取代或未取代的C3-C10环烷基,优选地,R10为甲基、异丙基、环丙基和1-甲基环丙基,其中Rd、Re和R10的碳原子上的氢均可各自独立被氘替换。
在另一优选例中,所述的式I化合物具有如下式所示的结构:
在另一优选例中,至少一个所述的R4选自下组:NRdRe;所述的Rd和Re各自独立地选自下组:H、取代或未取代的C1-C6烷基、取代或未取代的C3-C10环烷基、-C0-8-O-R8,-C0-8-C(O)OR8,-C0-8-OC(O)OR8,-C0-8-NR8R9,-C0-8-N(R8)C(O)R9,-C0-8-C(O)NR8R9、取代或未取代的C6-C10芳基;或Rd和Re共同形成取代或未取代的具有1-3个选自N、S和O的杂原子的5-10元杂环基;优选地,所述的取代基为羧基。
在另一优选例中,所述的为选自下组的结构:
在另一优选例中,所述的化合物选自下列化合物;
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
本发明的第二方面,提供了一种如本发明第一方面所述的式I化合物的制备方法,其特征在于,所述的方法包括选自合成方案1,2或3所示的步骤:
合成方案1:
(a)以中间体II和III为原料,通过钯催化剂催化的Sonogashira偶联反应得到目标产物I-1;
优选地,中间体II-2的制备方法如下:
(a)以II-1为原料,在路易斯酸催化下,发生卤代反应,得到中间体II-2;
优选地,中间体III的制备方法如下:
(a)以化合物III-1和III-2为原料,在钯催化剂和配体的条件下,发生偶联反应(如Suzuki,Buchwald等),得到中间体III-3;
(b)以III-3为原料,使用合适的试剂,移除硅基保护基,得到中间体III;
合成方案2:
(a)以化合物II-1为原料,与硝化剂反应(如浓硫酸/NaNO3,浓硫酸/发烟硝酸等),形成中间体IV-1;
(b)以IV-1为原料,在还原条件下(Pd-C/H2;锌粉/氯化铵;铁粉/醋酸等),发生还原反应,形成中间体IV-2;
(c)以IV-2和IV-3为原料,在碱性条件下,发生亲和取代反应得到酰胺中间体;而后在合适的脱水试剂(如PPh3/DDQ),发生环化反应,得到中间体IV-4;
(d)以IV-4和IV-5为原料,在催化剂和配体的条件下,发生偶联反应,形成中间体I-2;
合成方案3:
(a)以V-1和V-2为原料,在催化剂和配体的条件下,发生偶联反应,形成中间体V-3;
(d)以IV-4和合适的硼源(如B2Pin2)为原料,在催化剂和配体的条件下,发生偶联反应,形成中间体V-4;
(d)以V-4和IV-4为原料,在催化剂和配体的条件下,发生偶联反应,形成目标产物I-3;
上述X1-X12、R1-R9、t、m、n的定义如前所述。
本发明的第三方面,提供了一种药物组合物,包含(1)如本发明第一方面所述的化合物或其立体异构体或互变异构体,或其药学上可接受的盐、水合物或溶剂化物;(2)药学上可接受的载体。
本发明的第四方面,提供了一种如本发明第以方面所述的化合物或其立体异构体或互变异构体,或其药学上可接受的盐、水合物或溶剂化物或如本发明第三方面所述的药物组合物的用途,其特征在于,用于制备预防和/或治疗与PD-1/PD-L1的活性或表达量相关的疾病(HBV、HCV、实体瘤、血液瘤等)的药物组合物。
本发明的第五方面,提供了一种PD-1/PD-L1调节剂,所述调节剂包含本发明第一方面所述的化合物、或其立体异构体或互变异构体、或其药学上可接受的盐、水合物或溶剂化物。
在另一优选例中,所述的药物组合物被用于治疗选自下组的疾病:癌症、感染性疾病、自身免疫性疾病。
在另一优选例中,所述的癌症选自下组:胰腺癌,膀胱癌,结肠直肠癌,乳腺癌,前列腺癌,肾癌,肝细胞癌,肺癌,卵巢癌,宫颈癌,胃癌,食道癌,黑色素瘤,神经内分泌癌,中枢神经系统癌,脑癌,骨癌,软组织肉瘤,非小细胞肺癌癌症,小细胞肺癌或结肠癌、皮肤癌、肺癌、泌尿系肿瘤、血液肿瘤、胶质瘤、消化系统肿瘤、生殖系统肿瘤、淋巴瘤、神经系统肿瘤、脑瘤、头颈癌。
在另一优选例中,所述癌症选自下组:急性淋巴细胞白血病(ALL),急性髓性白血病(AML),慢性淋巴细胞白血病(CLL),小淋巴细胞性淋巴瘤(SLL),骨髓增生异常综合征(MDS),骨髓增生性疾病(MPD),慢性粒细胞白血病(CML),多发性骨髓瘤(MM),非霍奇金淋巴瘤(NHL),套细胞淋巴瘤(MCL),滤泡性淋巴瘤,Waldestrom巨球蛋白血症(WM),T细胞淋巴瘤,B细胞淋巴瘤或弥漫性大B细胞淋巴瘤(DLBCL)。
在另一优选例中,所述的感染性疾病选自细菌感染、病毒感染。
在另一优选例中,所述的自身免疫性疾病选自器官特异性自身免疫病、系统性自身免疫病。
在另一优选例中,所述的器官特异性自身免疫病包括慢性淋巴细胞性甲状腺炎、甲状腺功能亢进、胰岛素依赖型糖尿病、重症肌无力、溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合症、原发性胆汁性肝硬化、多发性脑脊髓硬化症、急性特发性多神经炎。
在另一优选例中,所述的系统性自身免疫病包括类风湿关节炎、系统性红斑狼疮、系统性血管炎、硬皮病、天疱疮、皮肌炎、混合性结缔组织病、自身免疫性溶血性贫血。
在另一优选例中,所述的药物组合物还用于改善慢性乙型肝炎(CHB)患者T细胞功能。
在另一优选例中,所述的抑制剂还包括至少一种选自下组的治疗剂:纳武单抗,派姆单抗,atezolizumab,或伊匹单抗。
本发明的第六方面,提供了一种体内调节PD-1/PD-L1相互作用的方法,其特征在于,包括步骤:将本发明第一方面所述的化合物、或其立体异构体或互变异构体、或其药学上可接受的盐、水合物或溶剂化物与PD-L1蛋白接触。
具体实施方式
本发明人经过广泛而深入的研究,发现了一类具有优异的调节效果的PD-1/PD-L1相互作用调节剂。在此基础上,发明人完成了本发明。
定义
如本文所用,术语“烷基”包括直链或支链的烷基。例如C1-C8烷基表示具有1-8个碳原子的直链或支链的烷基,例如甲基、乙基、丙基、异丙基、丁基、异丁基、叔丁基等。
如本文所用,术语“烯基”包括直链或支链的烯基。例如C2-C6烯基指具有2-6个碳原子的直链或支链的烯基,例如乙烯基、烯丙基、1-丙烯基、异丙烯基、1-丁烯基、2-丁烯基、或类似基团。
如本文所用,术语“炔基”包括直链或支链的炔基。例如C2-C6炔基是指具有2-6个碳原子的直链或支链的炔基,例如乙炔基、丙炔基、丁炔基、或类似基团。
如本文所用,术语“C3-C10环烷基”指具有3-10个碳原子的环烷基。其可以是单环,例如环丙基、环丁基、环戊基、环己基、或类似基团。也可以是双环形式,例如桥环或螺环形式。
如本文所用,术语“C1-C8烷胺基”是指被C1-C8烷基所取代的胺基,可以是单取代或双取代的;例如,甲胺基、乙胺基、丙胺基、异丙胺基、丁胺基、异丁胺基、叔丁胺基、二甲胺基、二乙胺基、二丙胺基、二异丙胺基、二丁胺基、二异丁胺基、二叔丁胺基等。
如本文所用,术语“C1-C8烷氧基”是指具有1-8个碳原子的直链或支链的烷氧基;例如,甲氧基、乙氧基、丙氧基、异丙氧基、丁氧基、异丁氧基、叔丁氧基等。
如本文所用,术语“具有1-3个选自下组N、S和O的杂原子的3-10元杂环烷基”是指具有3-10个原子的且其中1-3个原子为选自下组N、S和O的杂原子的饱和或部分饱和的环状基团。其可以是单环,也可以是双环形式,例如桥环或螺环形式。具体的实例可以为氧杂环丁烷、氮杂环丁烷、四氢-2H-吡喃基、哌啶基、四氢呋喃基、吗啉基和吡咯烷基等。
如本文所用,术语“C6-C10芳基”是指具有6-10个碳原子的芳基,例如,苯基或萘基等类似基团。
如本文所用,术语“具有1-3个选自下组N、S和O的杂原子的5-10元杂芳基”指具有5-10个原子的且其中1-3个原子为选自下组N、S和O的杂原子的环状芳香基团。其可以是单环,也可以是稠环形式。具体的实例可以为吡啶基、哒嗪基、嘧啶基、吡嗪基、三嗪基、吡咯基、吡唑基、咪唑基、(1,2,3)-三唑基以及(1,2,4)-三唑基、四唑基、呋喃基、噻吩基、异恶唑基、噻唑基、恶唑基等。
本发明所述的基团除非特别说明是“取代的或未取代的”,否则本发明的基团均可被选自下组的取代基所取代:卤素、腈基、硝基、羟基、氨基、C1-C6烷基-胺基、C1-C6烷基、C2-C6烯基、C2-C6炔基、C1-C6烷氧基、卤代C1-C6烷基、卤代C2-C6烯基、卤代C2-C6炔基、卤代C1-C6烷氧基、烯丙基、苄基、C6-C12芳基、C1-C6烷氧基-C1-C6烷基、C1-C6烷氧基-羰基、苯氧羰基、C2-C6炔基-羰基、C2-C6烯基-羰基、C3-C6环烷基-羰基、C1-C6烷基-磺酰基等。
如本文所用,“卤素”或“卤原子”指F、Cl、Br、和I。更佳地,卤素或卤原子选自F、Cl和Br。“卤代的”是指被选自F、Cl、Br、和I的原子所取代。
除非特别说明,本发明所描述的结构式意在包括所有的同分异构形式(如对映异构,非对映异构和几何异构体(或构象异构体)):例如含有不对称中心的R、S构型,双键的(Z)、(E)异构体等。因此,本发明化合物的单个立体化学异构体或其对映异构体、非对映异构体或几何异构体(或构象异构体)的混合物都属于本发明的范围。
除非特别说明,本发明所描述的结构式意在包括所有可能的氘代衍生物(即,分子中的一个或多个氢原子被D取代)。
如本文所用,术语“互变异构体”表示具有不同能量的结构同分异构体可以超过低能垒,从而互相转化。比如,质子互变异构体(即质子移变)包括通过质子迁移进行互变,如1H-吲唑与2H-吲唑。化合价互变异构体包括通过一些成键电子重组而进行互变。
如本文所用,术语“溶剂合物”是指本发明化合物与溶剂分子配位形成特定比例的配合物。
如本文所用,术语“水合物”是指本发明化合物与水进行配位形成的配合物。
活性成分
如本文所用,“本发明化合物”指式I所示的化合物,并且还包括及式I化合物的各种晶型形式、药学上可接受的盐、水合物或溶剂合物。
优选的本发明化合物包括化合物1-360(包括各化合物的各类R构型和/或S构型的立体异构体,和/或E-/Z-的顺反异构体)。
在另一优选例中,所述的药用盐包括与无机酸、有机酸、碱金属离子、碱土金属离子或能提供生理上可接受的阳离子的有机碱结合形成的盐以及铵盐。
在另一优选例中,所述的无机酸选自盐酸、氢溴酸、磷酸或硫酸;所述的有机酸选自甲磺酸、对甲苯磺酸、三氟乙酸、枸杞酸、马来酸酒石酸、富马酸、柠檬酸或乳酸;所述的碱金属离子选自锂离子、钠离子、钾离子;所述的碱土金属离子选自钙离子、镁离子;所述的能提供生理上可接受的阳离子的有机碱选自甲胺、二甲胺、三甲胺、哌啶、吗啉或三(2-羟乙基)胺。
在本发明范围内的所有这些盐都可采用常规方法制备。在所述的通式I化合物及其溶剂化物和其盐的制备过程中,不同的结晶条件可能出现多晶或共晶。
本发明制备方法中的起始原料及中间体容易得到,各步反应可依据已报道的文献或对本领域熟练技术人员来说可以用有机合成中的常规方法很容易合成。通式I所述化合物可以溶剂化物或非溶剂化物的形式存在,利用不同的溶剂进行结晶可能得到不同的溶剂化物。
药物组合物和施用方法
由于本发明化合物具有优异的PD-1/PD-L1相互作用的调节活性,因此本发明化合物及其各种晶型,药学上可接受的无机或有机盐,水合物或溶剂合物,以及含有本发明化合物为主要活性成分的药物组合物可用于预防和/或治疗(稳定、减轻或治愈)PD-1/PD-L1相互作用相关疾病(例如,癌症、感染性疾病、自身免疫性疾病)。
本发明的药物组合物包含安全有效量范围内的本发明化合物及药学上可以接受的赋形剂或载体。其中“安全有效量”指的是:化合物的量足以明显改善病情,而不至于产生严重的副作用。通常,药物组合物含有1-2000mg本发明化合物/剂,更佳地,含有10-200mg本发明化合物/剂。较佳地,所述的“一剂”为一个胶囊或药片。
“药学上可接受的载体”指的是:一种或多种相容性固体或液体填料或凝胶物质,它们适合于人使用,而且必须有足够的纯度和足够低的毒性。“相容性”在此指的是组合物中各组份能和本发明化合物以及它们之间相互掺和,而不明显降低化合物的药效。药学上可以接受的载体部分例子有纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)、明胶、滑石、固体润滑剂(如硬脂酸、硬脂酸镁)、硫酸钙、植物油(如豆油、芝麻油、花生油、橄榄油等)、多元醇(如丙二醇、甘油、甘露醇、山梨醇等)、乳化剂(如吐温)、润湿剂(如十二烷基硫酸钠)、着色剂、调味剂、稳定剂、抗氧化剂、防腐剂、无热原水等。
本发明化合物或药物组合物的施用方式没有特别限制,代表性的施用方式包括(但并不限于):口服、肠胃外(静脉内、肌肉内或皮下)。
用于口服给药的固体剂型包括胶囊剂、片剂、丸剂、散剂和颗粒剂。在这些固体剂型中,活性化合物与至少一种常规惰性赋形剂(或载体)混合,如柠檬酸钠或磷酸二钙,或与下述成分混合:(a)填料或增容剂,例如,淀粉、乳糖、蔗糖、葡萄糖、甘露醇和硅酸;(b)粘合剂,例如,羟甲基纤维素、藻酸盐、明胶、聚乙烯基吡咯烷酮、蔗糖和阿拉伯胶;(c)保湿剂,例如,甘油;(d)崩解剂,例如,琼脂、碳酸钙、马铃薯淀粉或木薯淀粉、藻酸、某些复合硅酸盐、和碳酸钠;(e)缓溶剂,例如石蜡;(f)吸收加速剂,例如,季胺化合物;(g)润湿剂,例如鲸蜡醇和单硬脂酸甘油酯;(h)吸附剂,例如,高岭土;和(i)润滑剂,例如,滑石、硬脂酸钙、硬脂酸镁、固体聚乙二醇、十二烷基硫酸钠,或其混合物。胶囊剂、片剂和丸剂中,剂型也可包含缓冲剂。
固体剂型如片剂、糖丸、胶囊剂、丸剂和颗粒剂可采用包衣和壳材制备,如肠衣和其它本领域公知的材料。它们可包含不透明剂,并且,这种组合物中活性化合物或化合物的释放可以延迟的方式在消化道内的某一部分中释放。可采用的包埋组分的实例是聚合物质和蜡类物质。必要时,活性化合物也可与上述赋形剂中的一种或多种形成微胶囊形式。
用于口服给药的液体剂型包括药学上可接受的乳液、溶液、悬浮液、糖浆或酊剂。除了活性化合物外,液体剂型可包含本领域中常规采用的惰性稀释剂,如水或其它溶剂,增溶剂和乳化剂,例知,乙醇、异丙醇、碳酸乙酯、乙酸乙酯、丙二醇、1,3-丁二醇、二甲基甲酰胺以及油,特别是棉籽油、花生油、玉米胚油、橄榄油、蓖麻油和芝麻油或这些物质的混合物等。
除了这些惰性稀释剂外,组合物也可包含助剂,如润湿剂、乳化剂和悬浮剂、甜味剂、矫味剂和香料。
除了活性化合物外,悬浮液可包含悬浮剂,例如,乙氧基化异十八烷醇、聚氧乙烯山梨醇和脱水山梨醇酯、微晶纤维素、甲醇铝和琼脂或这些物质的混合物等。
用于肠胃外注射的组合物可包含生理上可接受的无菌含水或无水溶液、分散液、悬浮液或乳液,和用于重新溶解成无菌的可注射溶液或分散液的无菌粉末。适宜的含水和非水载体、稀释剂、溶剂或赋形剂包括水、乙醇、多元醇及其适宜的混合物。
本发明化合物可以单独给药,或者与其他药学上可接受的化合物(例如其他抗癌制剂)联合给药。
联合给药时,所述药物组合物还包括与一种或多种(2种,3种,4种,或更多种)其他药学上可接受的化合物。该其他药学上可接受的化合物中的一种或多种(2种,3种,4种,或更多种)可与本发明的化合物同时、分开或顺序地用于预防和/或治疗PD-1/PD-L1相互作用相关疾病。
使用药物组合物时,是将安全有效量的本发明化合物适用于需要治疗的哺乳动物(如人),其中施用时剂量为药学上认为的有效给药剂量,对于60kg体重的人而言,日给药剂量通常为1~2000mg,优选20~500mg。当然,具体剂量还应考虑给药途径、病人健康状况等因素,这些都是熟练医师技能范围之内的。
本发明的主要优点包括:
(1)本发明化合物对PD-1/PD-L1相互作用具有很高的调节活性,与PD-L1蛋白具有很强的结合能力,并具有解除PD-L1抑制IFNγ的能力。
(2)本发明的化合物具有更好的溶解性较好;对正常细胞的毒性非常低,因而可以在较大的剂量范围内应用于治疗对象。
(3)相较于现有技术的化合物,本发明的化合物具有更好的溶解性,因此具有良好的成药性,相较于现有化合物而言,本发明化合物在体内实验之中表现出良好的生物利用度,除此之外,相较于现有化合物,本发明的化合物极易制成药学上可接受的盐,因而有助于进一步形成制剂。
(4)体内药效研究表明,本发明化合物无论从肿瘤体积还是重量上,都可显著的抑制皮下肿瘤的生长,并可明显增加小鼠血液中、脾脏中各淋巴细胞数量。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。除非另外说明,否则百分比和份数是重量百分比和重量份数。
以下实施例中所用的实验材料和试剂如无特别说明均可从市售渠道获得。
通用材料及测试方法:
实施例中涉及到的仪器及原料说明如下:
核磁共振氢谱是Bruker AV-400(400MHz)核磁仪分析得到。
化学位移以四甲基硅烷为内标来记录,以ppm为单位来表示(CDCl3:δ7.26ppm)。记录的数据信息如下:化学位移及其裂分和偶合常数(s:单重峰;d:双重峰;t:三重峰;q:四重峰;br:宽峰;m:多重峰)。
质谱数据除其他需要,都采用菲尼根高级LCQ公司(Finnigan LCQ Advantage)的液质联用仪进行分析,所有反应都在干燥氩气保护的无水无氧条件下进行操作。固体金属有机化合物在氩气保护干燥箱中进行储藏。
四氢呋喃和乙醚是经过蒸馏得到,蒸馏时在其中加入金属钠和二苯甲酮。二氯甲烷,戊烷和己烷是用氢化钙来处理。
本发明中涉及的特殊原料和中间体由天津长森药业有限公司等订制加工提供,其他所有化学试剂从上海化学试剂公司、阿尔得里奇公司(Aldrich)、阿克罗公司(Acros)等试剂供应商购买。如合成过程中反应所需的中间体或产物不够下一步试验,则重复多次合成至足够数量为止。
本发明所涉及的原料和试剂除特殊说明外均可市售或订制加工购买得到。
本发明中化合物可含有一个或多个不对称中心,因此该系列化合物可为消旋或者单一对映体形式。本发明所制备的化合物是纯度高于95%的杂环化合物,每个最终产物的结构表征分别由MS或/和氢谱核磁共振(1H NMR)分析确定。以下通过实施例说明本发明各类化合物和中间体的合成。
实施例1化合物001的合成
步骤1-1:
1.3克1-1溶于DCM-3M H2SO4(1∶1)200ML中,冰浴,5度下0.71g硝酸钠加入到反应体系中,氮气保护,室温反应过夜。TLC点板显示1-1消失,LCMS分析得知产物生成。柱层析纯化得产物1-2600mg,MS-APCI:208[M+H]+and 1-3 300mg,MS-APCI:208[M+H]+.
步骤1-2:
将4.5克化合物1-2溶于200毫升DCM(于500毫升单口烧瓶中),加入6.3克NIS,氩气保护。室温反应过夜。TLC点板1-2反应完全。反应液加2M HCl 100mL,分液,干燥。旋干过柱(Hep-DCM 1∶1,then DCM)纯化得到6g产物,淡黄色固体。MS-APCI:334[M+H]+.
步骤1-3:
在50毫升三口瓶中加入945毫克化合物1-4,636毫克化合物1-5,25毫克CuI和25毫克Pd(PPh3)2Cl2,氩气保护,加入20毫升DMF和1.2毫升DIPEA,55℃反应3小时。TLC点板原料消失。反应液加入到300毫升冰水中,乙酸乙酯300毫升萃取两次,2M NaOH洗涤一次,干燥旋干。过柱(DCM-MeOH 10∶1)纯化,得到220mg浅黄色固体。MS-APCI:654[M+H]+.
步骤1-4:
将215毫克化合物1-6,248毫克methyl azetidine-3-carboxylatehydrochloride,125毫克Na(CN)BH3溶于10毫升THF中,氩气保护,加入167毫克三乙胺,70℃反应24小时。反应液加入到100毫升冰水中,EA 100毫升萃取两次,干燥。过柱(DCM-MeOH100,50∶1,10∶1,5∶1)纯化,得到53mg浅黄色固体1-7,MS-APCI:753[M+H]+.
步骤1-5:
将53毫克原料1-7溶于5毫升MeOH,加入2毫升2M NaOH,26度反应5小时。反应液40度旋干,残留固体加入50毫升水,2M HCl调节PH值为7,虑出固体,水洗,THF洗,干燥,进一步制备纯化得黄色固体5毫克。MS-APCI:739[M+H]+
1H NMR(400MHz,DMSO-d6)δ9.34(s,1H),9.00(s,1H),8.46(s,1H),8.34(d,J=8.0Hz,1H),8.08(d,J=8.0Hz,1H),7.77(d,J=8.0Hz,1H),7.44(t,J=8.0Hz,1H),7.35-7.25(m,3H),7.19(d,J=8.0Hz,1H),6.91(d,J=8.0Hz,1H),6.52(m,1H),4.75(brs,1H),4.20(brs,1H),3.84-3.74(m,2H),3.37-2.83(m,3H),2.66-2.28(m,2H),2.21(s,3H),2.18-2.06(m,1H),2.06(s,3H),1.96-1.58(m,5H),1.43(m,1H).
步骤1-6:
取氨基原料1-9(30克)溶于乙腈-Water(1∶1)400毫升中,氮气保护,体系清澈,冰浴,在内温0~5度下加入对甲苯磺酸水合物(901克),搅拌10分钟,体系呈粉色浑浊,内温0~5度下滴加NaNO2水溶液(22克,45毫升)。反应30分钟,体系清澈;避光,0~5度下滴加碘化钾水溶液(67克,60毫升),自然升至室温下反应;TLC跟踪;后处理:冰浴下加入饱和亚硫酸钠淬灭,HEP萃取,饱和食盐水洗1次,拌样,过柱:HEP冲下产品,浓缩得黄棕色液体46.9克,收率:98.1%。MS-APCI:296[M+H]+.
步骤1-7:
取碘原料1-10(1克),CuI(0.03克),Pd(Ph3P)2Cl2(0.12克)加入50毫升反应瓶中,氮气置换3次,加入无水DMF(20毫升),体系呈红褐色清澈;加入三乙胺(1.7克),体系呈棕黄色清澈;氮气置换3次,避光,加入炔原料1-11(0.52克),室温下反应;TLC跟踪;后处理:冰浴下加入饱和氯化铵淬灭,MTBE萃取2次,饱和食盐水洗5次,拌样,过柱:HEP冲下产品,浓缩得黄棕色液体1.03克,收率:95%。MS-APCI:309[M+H]+.
步骤1-8:
取溴原料1-12(1.1克),硼酸酯原料1-14(1g,WO2018119286),Pd(dppf)Cl2(0.12克)和碳酸钠(0.62克)加入50毫升反应瓶中,氮气置换3次,加入1,4-二氧六环(8毫升)和水2毫升,90度下反应;TLC跟踪;后处理:冰浴下加入饱和氯化铵淬灭,MTBE萃取2次,饱和食盐水洗5次,拌样,过柱:(HEP-DCM 100,50∶1,10∶1,5∶1)冲下产品,浓缩得黄色固体0.5克,收率:41%。MS-APCI:563[M+H]+
步骤1-10:
炔原料1-15(1.1克)加入到THF(15毫升)中,氮气置换3次,加入1M TBAF 1毫升,室温下反应;TLC跟踪;后处理:旋干THF,加入水5毫升,乙酸乙酯萃取2次,饱和食盐水洗2次,拌样,过柱:(DCM-MeOH 100,50∶1,10∶1,5∶1)冲下产品,
浓缩得黄色固体1.0克,收率:83%。MS-APCI:449[M+H]+.
实施例2化合物002的合成
步骤2-1:
取1-1(1.1g),碳酸氢钠(0.57g)加入100mL三口瓶,加入甲醇(25mL)和水(5mL)溶解,冰浴降温至5℃。缓慢加入NIS(1.52g),全部加入后自然升温,过夜反应。TLC检测原料反应完全。旋干甲醇,加入1M盐酸调节至pH<3,大量白色固体析出。过滤,滤饼固体加入到0.5M盐酸(100mL)中搅拌30分钟,再次过滤,所得滤饼固体用EA溶解,柱层析,得淡黄/白色固体产物,0.7g.MS-APCI:289[M+H]+
步骤2-2:
100mL两口瓶中,将2-1(1.5g)溶于DMF(20mL),加入Zn(CN)2(1.3g),Pd(PPh3)4(1.2g),N2保护,105度反应1h,TLC点板原料反应完全。冷却后反应液加EA/HEP稀释,过滤。滤液饱和NaCl洗,EA萃取。过柱纯化,得到纯品0.9g,黄色固体。MS-APCI:188[M+H]+
步骤2-3:
25mL两口瓶中,将2-2(1.5g)悬浮于DCM(20mL)中,室温下加入NIS(2.0g),反应10分钟,TLC点板原料消失。反应液加饱和NaHCO3,水相调pH=2,DCM萃取3次,DCM层用10%Na2S2O3洗,干燥,旋干得到1.9g产物,棕色固体。MS-APCI:314[M+H]+
步骤2-4:
15mL反应管中,将2-3(1.6g),2-4(1.3g,WO2018195321),Pd(PPh3)2Cl2(350mg),CuI(50mg),DIPEA(3g,6.5mmol)溶于DMF(8mL),N2保护,85度反应2h。TLC检测原料消失。反应完全后,往反应液加水/DCM萃取。干燥,旋干。剩余物用EA/HEP(20mL,1∶1)打浆。所得固体过柱纯化,纯DCM洗脱,得到800mg产物,黄色固体。MS-APCI:355[M+H]+
步骤2-5:
15mL反应管中,将2-5(150mg),1-7(135mg),NaBH3CN(39mg),TEA(83mg)加入到THF(5mL)中,70度反应5h。TLC检测1-6消失。反应液旋干,加水EA萃取。干燥EA,旋干,过柱纯化,得到纯品1-8(120mg),黄色固体。MS-APCI:454[M+H]+
步骤2-6:
将化合物2-6(100mg),1-14(100mg,WO2018119286),Pd(dppf)Cl2/DCM(16.7mg),Na2CO3(57.2mg)置于反应瓶,N2脱气保护,3mL dioxane/0.6mL水注入反应瓶中,90度反应1小时。TLC点板反应完成。反应液加2mL水,EA萃取。干燥EA,旋干,过柱纯化,得到产物80mg,黄色固体。MS-APCI:733[M+H]+
步骤2-7:
将2-7(80mg)溶于2mL THF,加入2mL水,加热LiOH(7.8mg),室温反应1h。TLC检测反应完成。反应液40度旋干,加2M HCl调节PH值为7,虑出固体,水洗,干燥,进一步制备纯化得黄色固体50mg。MS-APCI:719[M+H]+
1H NMR(400MHz,DMSO-d6)δ9.30(s,1H),8.84(d,J=2.0Hz,1H),8.43(d,J=8.1Hz,1H),8.16(d,J=1.9Hz,1H),8.04(d,J=5.8Hz,1H),7.84(s,1H),7.81(dd,J=7.9,1.3Hz,1H),7.46(t,J=7.7Hz,1H),7.32(t,J=7.9Hz,1H),7.29(d,J=1.3Hz,1H),7.26(dd,J=7.6,1.3Hz,1H),7.16(d,J=5.8Hz,1H),6.90(d,J=7.5Hz,1H),4.69(s,1H),4.20(s,1H),3.88-3.71(m,2H),3.50-3.39(m,11H),3.19-2.79(m,3H),2.76-2.58(m,2H),2.40-2.28(m,1H),2.22(s,3H),2.08(s,3H),2.00(dq,J=14.1,7.4Hz,1H),1.87(d,J=12.8Hz,1H),1.71(s,1H),1.57(t,J=13.0Hz,2H).
实施例3化合物003的合成
步骤3-1:
将化合物3-1(40g,230.7mmol),3-2(58.5g,230.7mmol,WO2012031004),Pd(dppf)Cl2/DCM(10.2g,0.05eq),Na2CO3(53g,2eq)依次加入到dioxane/H2O(300mL,5∶1)中,脱气3次,N2保护,80度反应1小时,TLC显示反应完成。反应液过滤,滤液旋干。加EA溶解,往EA中加入500mL饱和食盐水。分液。干燥EA层,旋干。所得固体用EA/HEP(200mL,1∶3)打浆,过滤,得到40g黄色固体。
步骤3-2:
3-3(66g,249mmol)溶于500mL THF,冷至0度,滴加甲醇钠溶液(50mL,5N inMeOH)。滴完后0度反应30分钟。0度下,往反应液中滴加4N HCl/MeOH至pH=7。旋走THF。剩余物用1L DCM溶解,加入2L水洗,分液。干燥DCM层。旋干。所得固体用EA/HEP(200mL,1∶3)打浆,过滤,得到60g黄色固体。
步骤3-3:
3L反应瓶,机械搅拌,CuBr(45.4g,316.5mmol)加入到HBr(500mL)中,冷至0度备用。而后将化合物3-4(55g,211mmol)悬浮在HBr(500mL)中,冷至0度,滴加NaNO2(17.5g,253mmol)(溶于50mL水中)水溶液。产生棕色烟雾。滴加完后,搅拌30分钟。将化合物3-4的HBr溶液一次性倒入到CuBr的HBr溶液中,反应液黑色,产生大量气泡。继续搅拌1h后,TLC监控SM1消失,产物点生成。反应液中加入2L水,再加入2L EtOAc,搅拌,固体溶解,分液。EA层干燥,旋干,过柱纯化(EA∶DCM∶HEP=1∶1∶4),得到产物45g,黄色固体。
步骤3-4:
化合物3-5(15g)悬浮于HCl/MeOH(250mL,4N)中(闷罐反应瓶),60度加热反应过夜。反应液变澄清。TLC检测5反应完全。反应液冷至室温后,黄色固体析出。将反应液旋干,剩余固体中加入饱和碳酸氢钠(300mL),加EA(200mL x 3)萃取。干燥EA层,旋干。所得固体用EA/HEP(240mL,1∶5)打浆。过滤,滤饼固体旋干,得到产物12g,黄色固体。
步骤3-5:
化合物3-6(31g,86.7mmol)溶于无水THF(300mL),冷至0度,分批加入LiBH4(2.1g,95.4mmol),0度下反应1h。TLC检测反应完成。反应液过滤。滤饼用DCM冲洗。滤液旋干。所得固体中加300mL水,EA(200mL X 3)萃取。干燥EA层,旋干,所得固体用EA/HEP(240mL,1∶5)打浆。过滤,滤饼固体旋干,得到产物24g,黄色固体。
步骤3-6:
将化合物3-7(32g,97.5mmol)溶于dioxane(500mL),加入MnO2(51g,585.4mmol),N2脱气保护,95度下反应5h。TLC检测反应完成。反应液过滤,滤液旋干。所得固体用EA/HEP(180mL,1∶5)打浆。过滤,滤饼固体旋干,得到产物24g,黄色固体。
步骤3-7:
将化合物3-8(22g,67.5mmol),R-3-羟基吡咯烷盐酸盐(16.6g,135mmol),TEA(20.5g,202.5mmol)加入到DCM(300mL)中,室温反应1小时后加入NaBH(OAc)3(21.5g,101.25mmol),继续反应1小时。TLC检测反应完成。后处理:反应液加水(300mL),分液,DCM层用饱和食盐水洗。分液,干燥DCM,旋干,过柱纯化(DCM∶MeOH=40∶1),得到15.3g产品,棕色油状物。
步骤3-8:
化合物3-9(2.0g,5mmol),Bpin2(6.37g,25.1mmol),Pd(PPh3)2Cl2(352mg,0.5mmol),KOAc(984.6mg,10mmol)加入到dioxane(40mL)中,脱气3次,N2保护,90度反应过夜。反应完全后,过滤。滤液旋干。加30mL DCM溶解后加入50g硅胶拌样。过硅胶柱纯化,洗脱梯度:EA=100%(500mL),EA∶MeOH=40∶1(2050mL)。得到产物900mg棕色油状物。
步骤3-9:
将原料3-11(51g,0.34mol)溶于500ml甲醇中,加入300ml水,加入碳酸氢钠(28.9g,0.34mmol),0℃左右加入NIS的甲醇溶液,加完反应过夜。后处理:浓缩干加入500ml水,3M盐酸调节PH至3,滤出固体,乙酸乙酯/乙醇打浆,滤出干燥得灰色固体146g。
步骤3-10:
将原料3-12(61g,230mmol)、ZnCN2(27g,230mmol),Pd(PPh3)4(12.8g,11mmol),混合于1000mL三口瓶中,加入1000mL DMF,N2置换3次,90℃下搅拌3h。TLC点板显示原料少量剩余,LCMS显示原料反应完全。
步骤3-11:
25mL两口瓶中,将3-13(15g)悬浮于DCM(20mL)中,室温下加入NIS(20g),反应10分钟,TLC点板原料消失。反应液加饱和NaHCO3,水相调pH=2,DCM萃取3次,DCM层用10%Na2S2O3洗,干燥,旋干得到19g产物,棕色固体。
步骤3-12:
15mL反应管中,将3-14(16g),2-4(1.3g,WO2018195321),Pd(PPh3)2Cl2(3.5g),CuI(500mg),DIPEA(30g,65mmol)溶于DMF(100mL),N2保护,85度反应2h。TLC检测原料消失。反应完全后,往反应液加水/DCM萃取。干燥,旋干。剩余物用EA/HEP(20mL,1∶1)打浆。所得固体过柱纯化,纯DCM洗脱,得到8g黄色固体。
步骤3-13:
15mL反应管中,将3-15(150mg),3-16(135mg),NaBH3CN(39mg),TEA(83mg)加入到THF(5mL)中,70度反应5h。TLC检测1-6消失。反应液旋干,加水EA萃取。干燥EA,旋干,过柱纯化,得到100mg黄色固体。
步骤3-14:
以化合物3-17(200mg)和3-10(180mg)为原料,按照步骤2-6的合成方法,得到产物120mg黄色固体
步骤3-15:
以化合物3-18(120mg)为原料,按照步骤2-7的合成方法,得到产物40mg黄色固体。MS(APCI):684.1H NMR(400MHz,DMSO-d6)δ8.32(s,1H),7.87(d,J=3.9Hz,1H),7.80(d,J=8.0Hz,1H),7.50(d,J=7.6Hz,1H),7.45(t,J=7.6Hz,1H),7.40(t,J=7.7Hz,1H),7.31(s,1H),7.27(d,J=7.6Hz,1H),7.24(d,J=7.4Hz,1H),5.29(t,J=5.0Hz,1H),4.65(d,J=4.6Hz,1H),4.29(d,J=7.0Hz,1H),4.15(s,1H),3.99(q,J=7.1Hz,2H),3.92(s,3H),3.71(d,J=4.3Hz,2H),2.79(t,J=6.8Hz,1H),2.68-2.60(m,4H),2.40(dd,J=9.7,4.0Hz,1H),2.30(q,J=1.9Hz,2H),2.21(s,3H),2.04(s,3H),1.96(d,J=7.0Hz,2H).
实施例4化合物004的合成
步骡4-1:
于250ml单口瓶中加入醋酸酐(75ml),浓硝酸(5ml),分批加入原料3-13(5.0g,28.9mmol),水浴下搅拌,20min后,有沉淀形成,TLC点板监测,反应完毕,滤出沉淀,抽干,打浆,拉干得白色固体4.5g。
步骤4-2:
于500ml单口瓶中加入THF(200ml),原料4-1(5.0g,23mmol)和TFA(0.2mL),Pt/C,H2置换3次,在室温下搅拌,反应1小时后,TLC点板监测,原料反应完毕,滤出Pt/C,滤液直接用于下一步。
步骤4-3:
上述滤液4-2(10.0g,45.8mmol)的THF溶液中加入180mmol Et3N,将3-6(10.74g,46mmol,Organic Letters,2019,21,5971-5976)用15ml DCM溶解,缓慢加入其中,室温下反应1hour,出现大量浑浊,滤出固体,乙酸乙酯打浆纯化得18g灰白色固体。
步骤4-4:
室温下将PPh3(9.7g,37mmol)溶于甲苯,缓慢加入DDQ(8.4g,37mmol)搅拌均匀,此时体系悬浊,加入原料4-4(7.1g,18.5mmol),于110℃下反应1hour,TLC点板,产物主要,倒出清液,浓缩干,EA打浆,得白色固体3.7g.
步骤4-5:
以化合物4-5(1g,2.72mmol)和3-16(902mg,5.45mmol)为原料,按照步骤3-13的合成方法,制得白色固体0.8g。
步骤4-6:
以化合物4-6(200mg,0.416mmol)和1-14(230mg,0.5mmol,WO2018119286)为原料,按照步骤2-6的合成方法,制得白色固体180mg。
步骤4-7:
以化合物4-7(120mg)为原料,按照步骤2-7的合成方法,得到产物38mg黄色固体。MS(APCI):720.1H NMR(400MHz,DMSO-d6)δ9.30(s,1H),8.83(d,J=2.0Hz,1H),8.45(d,J=8.2Hz,1H),8.15(d,J=1.9Hz,1H),8.12(d,J=7.9Hz,1H),8.04(d,J=5.8Hz,1H),7.98(d,J=9.9Hz,1H),7.52(t,J=7.7Hz,1H),7.41(d,J=7.5Hz,1H),7.33(t,J=7.9Hz,1H),7.15(d,J=5.8Hz,1H),6.89(d,J=7.5Hz,1H),4.38-4.26(m,1H),4.24-4.14(m,1H),3.78(q,J=13.7Hz,2H),3.24-3.15(m,2H),3.08-2.99(m,2H),2.93-2.76(m,2H),2.76-2.64(m,2H),2.63-2.54(m,3H),2.44(s,3H),2.35(dd,J=9.7,3.6Hz,1H),2.25-2.16(m,2H),2.10-2.05(m,3H),2.00(dt,J=13.5,7.3Hz,1H),1.95-1.87(m,2H),1.59-1.50(m,1H).
实施例5化合物005的合成
步骤5-1:
以化合物4-2(10g,45.8mmol)和5-1(11.6g,45.8mmol,WO2017059135)为原料,按照步骤4-3的合成方法,得到灰白色固体15g。
步骤5-2:
以化合物5-2(2g)为原料,按照步骤4-4的合成方法,制备得到灰白色固体1.1g。MS(APCI):387[M+H]+
步骤5-3:
以化合物5-3(1g,2.58mmol)和化合物3-16(0.85g,5.16mmol)为原料,按照步骤3-13的合成方法,制备得到灰白色固体0.9g。MS(APCI):500[M+H]+
步骤5-4:
以化合物5-4(200mg)和5-5(200mg,WO2018119286)为原料,按照步骤2-6的合成方法,制得白色固体210mg。
步骤5-5:
以化合物5-6(120mg)为原料,按照步骤2-7的合成方法,得到产物51mg黄色固体。MS(APCI):760.1H NMR(400MHz,DMSO-d6)δ9.89(s,1H),9.15(d,J=8.4Hz,1H),8.91(s,1H),8.28-8.15(m,2H),8.07(d,J=11.0Hz,1H),7.71(d,J=7.2Hz,2H),7.60-7.49(m,2H),7.34(d,J=5.8Hz,1H),7.09(d,J=7.5Hz,1H),5.31(s,1H),4.73(s,2H),4.35(dt,J=20.7,5.9Hz,2H),4.20(s,1H),3.93(s,1H),3.89-3.72(m,2H),2.87(dd,J=17.0,9.6Hz,2H),2.75-2.55(m,2H),2.40-2.29(m,2H),2.16-1.85(m,4H),1.56(s,2H),1.22(s,4H),0.84(t,J=6.8Hz,1H).
实施例6化合物006的合成
步骤6-1:
以化合物4-5(10g,0.0272mol)和6-1(9.3g,0.0544mol,WO2018136935)为原料,按照步骤3-13的合成方法,制得白色固体8g。
步骤6-2:
将化合物6-2(8g)进行手性柱拆分,得到化合物6-3(3.5g)。
步骤6-3:
将化合物6-3(3.5g)溶于TFA(10mL)中,而后室温搅拌1小时。悬干TFA,甲苯共沸一次。往残留液中加入饱和碳酸氢钠溶液和浓盐酸,调节PH至2-3,出现大量固体,过滤,烘干,得淡棕色固体2g。
步骤6-3:
以化合物6-4(200mg,0.416mmol)和1-14(230mg,0.5mmol,WO2018119286)为原料,按照步骤2-6的合成方法,制得白色固体32mg。MS(APCI):720.1H NMR(400MHz,DMSO-d6)δ9.32(s,1H),8.86(s,1H),8.47(d,J=8.2Hz,1H),8.18(s,1H),8.15(d,J=7.8Hz,1H),8.06(d,J=5.8Hz,1H),8.02(s,1H),7.55(s,1H),7.43(d,J=7.6Hz,1H),7.35(s,1H),7.18(d,J=5.8Hz,1H),6.92(d,J=7.5Hz,1H),4.32(d,J=5.8Hz,1H),4.22(tt,J=6.9,3.4Hz,1H),3.81(q,J=13.7Hz,3H),3.07(q,J=9.3,8.0Hz,3H),2.89(s,2H),2.83(d,J=8.8Hz,2H),2.74(dd,J=10.0,6.3Hz,2H),2.63(dq,J=15.1,7.5Hz,3H),2.46(s,3H),2.37(dd,J=9.7,3.6Hz,2H),2.24(q,J=6.8Hz,2H),2.09(s,3H),2.01(dt,J=13.7,6.8Hz,2H),1.92(d,J=7.8Hz,2H),1.57(d,J=3.7Hz,2H)
实施例7化合物007的合成
步骤6-2:
将化合物6-2(8g)进行手性柱拆分,得到化合物7-1(4g)。
步骤6-3:
将化合物7-1(4g)溶于TFA(10mL)中,而后室温搅拌1小时。悬干TFA,甲苯共沸一次。往残留液中加入饱和碳酸氢钠溶液和浓盐酸,调节PH至2-3,出现大量固体,过滤,烘干,得淡棕色固体3.2g。
步骤6-3:
以化合物7-2(200mg,0.416mmol)和1-14(230mg,0.5mmol,WO2018119286)为原料,按照步骤2-6的合成方法,制得白色固体30mg。MS(APCI):720.1H NMR(400MHz,DMSO-d6)δ9.32(s,1H),8.86(d,J=2.0Hz,1H),8.46(d,J=8.1Hz,1H),8.18(s,1H),8.15(d,J=7.9Hz,1H),8.06(d,J=5.8Hz,1H),8.01(s,1H),7.55(t,J=7.7Hz,1H),7.43(d,J=7.4Hz,1H),7.35(t,J=7.9Hz,1H),7.18(d,J=5.8Hz,1H),6.92(d,J=7.5Hz,1H),4.36(t,J=6.0Hz,1H),4.21(dt,J=6.9,3.4Hz,1H),3.81(q,J=13.8Hz,2H),3.12-3.01(m,3H),2.89(p,J=7.5Hz,2H),2.79(s,1H),2.75(d,J=6.1Hz,1H),2.72(dd,J=6.3,3.4Hz,1H),2.62(dt,J=12.3,7.5Hz,4H),2.46(s,3H),2.37(dd,J=9.7,3.6Hz,1H),2.22(t,J=7.2Hz,2H),2.08(s,2H),2.00(dd,J=11.0,4.9Hz,2H),1.94(dd,J=8.9,6.0Hz,2H),1.57(qd,J=8.2,3.8Hz,2H)。
实施例8化合物008的合成
步骡8-1:
将化合物8-1(1.9g,6.41mmol,WO2016207226),8-2(1.1g,6.41mmol,WO2018006795),碳酸钠(1.36g,12.82mmol)和四三苯基膦钯(222mg,0.19mmol)依次加入装有dioxane/H2O(4∶1,25mL)的单口瓶中,氮气保护,于油浴80度下搅拌3小时,LC-MS检测反应。原料剩余约10%后,将反应冷却,过滤,悬干,DCM/H2O萃取,无水硫酸钠干燥,柱层析(纯PE过柱),得淡黄色固体650mg。ESI(APCI):306[M+H]+.
步骤8-2:
将化合物8-3(200mg,0.653mmol),R-3-羟基吡咯烷盐酸盐(121mg,0.98mmol)和三乙胺(0.09mL,0.653mmol)依次加入装有DCM(10mL)的单口瓶中,室温搅拌2小时后,往反应液中加入NaBH(OAc)3(415mg,1.96mmol),室温搅拌过夜,TLC检测反应。反应完全后,加水淬灭,卤水洗涤,无水硫酸钠干燥,柱层析,得200mg油状物。ESI(APCI):377[M+H]+.
步骤8-3:
将化合物8-5(1g,2.72mmol),B2Pin2(1.04g,4.08mmol),KOAc(668mg,6.81mmol),X-phos(258mg,0.544mmol)和Pd(dppf)2Cl2(221mg,0.272mmol)依次加入装有DMAc(20mL)的单口瓶中,氮气保护,于油浴90度下搅拌3.5小时,LC-MS检测反应。反应完全后,悬干溶剂,DCM/H2O萃取,无水硫酸钠干燥,柱层析,得黄色固体1g。ESI(APCI):415[M+H]+.
步骤8-4:
将化合物8-4(200mg,0.53mmol),8-6(240mg,0.58mmol),碳酸钠(168mg,1.59mmol)和Pd(dppf)2Cl2(44mg)依次加入装有dioxane/H2O(4∶1,5mL)的单口瓶中,于油浴100度下搅拌3小时,LC-MS监测反应。反应完全后,过滤,悬干溶剂,DCM/H2O萃取,无水硫酸钠干燥,柱层析,得油状物120mg。ESI(APCI):585[M+H]+.
步骤8-5:
将化合物8-7(120mg,0.205mmol),3-16(51mg,0.308mmol),三乙胺(0.03mL,0.205mmol)和NaBH3CN(126mg,0.616mmol)依次加入装有THF(5mL)的单口瓶中,于油浴70度搅拌过夜,LC-MS监测反应,反应完全后,加水淬灭,悬干溶剂,DCM/H2O萃取,无水硫酸钠干燥,柱层析,得油状物70mg。ESI(APCI):698[M+H]+.
步骤8-6:
将化合物8-8(70mg,0.1mmol)和LiOH(5mg,0.2mmol)依次加入装有THF/MeOH/H2O(2∶1∶1,4mL)的单口瓶中,室温搅拌1小时,TLC监测反应。反应完全后,加TFA调节PH至中性,用反相柱制备得10mg白色固体。ESI(APCI):684[M+H]+.1H NMR(400MHz,DMSO-d6)δ8.13(d,J=7.9Hz,1H),7.99(d,J=9.6Hz,1H),7.74(d,J=7.5Hz,1H),7.52(t,J=7.7Hz,1H),7.48-7.40(m,2H),7.36(t,J=7.5Hz,1H),7.18(d,J=7.7Hz,1H),7.14(d,J=7.4Hz,1H),4.68(br,1H),4.40-4.26(m,1H),4.22-4.15(m,1H),3.86(s,3H),3.67-3.48(m,2H),3.28-3.14(m,2H),3.09-2.98(m,1H),2.93-2.74(m,4H),2.74-2.51(m,3H),2.44(s,3H),2.44-2.34(m,3H),2.25-2.17(m,2H),2.02(s,3H),2.00-1.85(m,3H),1.58-1.51(m,1H).
实施例9化合物009的合成
步骤9-1:
将化合物6-2(1g)溶于TFA(5mL)中,而后室温搅拌1小时。悬干TFA,甲苯共沸一次。往残留液中加入饱和碳酸氢钠溶液和浓盐酸,调节PH至2-3,出现大量固体,过滤,烘干,得淡棕色固体0.5g。
步骤9-2:
将化合物9-1(0.5g,1.07mmol),环丙基磺酰胺(260mg,2.14mmol),DMAP(261mg,2.14mmol)和EDCI(410mg,2.14mmol)一次加入装有DCM(15mL)的单口瓶中,室温搅拌过夜,TLC检测反应。反应安全后,用饱和食盐水和0.5M稀盐酸水溶液洗涤,而后无水硫酸钠干燥有机层,柱层析,得淡黄色固体0.3g。
步骤9-3:
以化合物9-2(200mg)和1-14(240mg)为原料,按照步骤8-4的合成方法,制得淡黄色固体60mg。ESI(APCI):823[M+H]+.1H NMR(400MHz,DMSO-d6)δ9.30(s,1H),8.86(d,J=2.0Hz,1H),8.42(d,J=8.1Hz,1H),8.20(d,J=1.9Hz,1H),8.15-8.09(m,1H),8.04(t,J=6.0Hz,2H),7.53(t,J=7.7Hz,1H),7.41(d,J=7.5Hz,1H),7.33(t,J=7.9Hz,1H),7.16(d,J=5.8Hz,1H),6.91(d,J=7.5Hz,1H),4.42(d,J=6.3Hz,1H),4.23(tt,J=6.5,3.1Hz,1H),4.01-3.84(m,2H),3.30-3.17(m,3H),3.06(dt,J=16.6,6.8Hz,2H),2.98-2.75(m,5H),2.74-2.54(m,4H),2.44(s,3H),2.31-2.19(m,3H),2.07(s,3H),2.05-1.85(m,4H),1.64-1.55(m,1H).
实施例10化合物010的合成(222)
步骤10-1:
将004(30mg,0.0471mmol),NH4HCO3(7mg,0.0834mmol)和Boc2O(18mg,0.0834mmol)依次加入装有THF/Pyridine(6∶1,3.5mL)的单口瓶中,于室温搅拌1小时,LC-MS检测反应。反应完全后,加入TFA调节PH至7-8,而后反相柱制备得淡黄色固体10mg。ESI(APCI):719[M+H]+.1H NMR(400MHz,DMSO-d6)δ9.35(s,1H),8.97(s,1H),8.39(s,1H),8.32(d,J=8.2Hz,1H),8.16(d,J=7.9Hz,1H),8.08(d,J=5.7Hz,1H),7.58-7.47(m,2H),7.43(d,J=7.5Hz,1H),7.35(t,J=7.8Hz,1H),7.17(d,J=5.8Hz,1H),6.94(d,J=7.5Hz,1H),5.40-5.26(m,1H),4.57-4.32(m,2H),3.20-2.89(m,7H),2.46(s,3H),2.31-2.21(m,1H),2.19-2.08(m,2H),2.06(s,3H),2.01-1.89(m,2H),1.85-1.75(m,1H).
实施例11化合物011的合成
步骤11-1:
将化合物5-3(5g,12.9mmol),S-叔丁基亚磺酰胺(4.69g,38.7mmol)和四钛酸乙酯(11.77g,51.60mmol)依次加入甲苯(50mL)中,氮气保护,升至70度加热搅拌过夜,TLC检测反应。反应完全后,冷却至室温,直接用于下一步。
步骤11-2:
将上述反应液冷却至-70度,而后往其中加入THF(20mL)和NaBH4(3.9g,103.2mmol),并保温搅拌1小时。而后慢慢升至室温搅拌1小时,TLC检测反应。反应完全后,往其中加入饱和氯化铵水溶液。而后乙酸乙酯萃取,无水硫酸钠干燥,柱层析,得黑灰色固体5g。
步骤11-3:
将化合物11-2(1g,2.03mmol)溶于DCM(5mL)中,冰浴下搅拌。而后往溶液中加入氯化氢的dioxane溶液(3M,1mL),加毕升至室温搅拌1小时,TLC检测反应。反应完全后,过滤,用乙酸乙酯淋洗固体,烘干,得黑灰色固体788mg。
步骤11-4:
将化合物11-3(300mg,0.77mmol),碳酸钾(213mg)加入DMF(5mL)中,而后往反应液中加入3-溴丙酸甲酯(129mg),而后每隔1小时加入3-溴丙酸甲酯(129mg),共加3次,LC-MS检测反应,直至产物不再增加。用DCM和水萃取,无水硫酸钠干燥,柱层析,得产物和原料的混合物100mg。
步骤11-5:
将上述混合物溶于THF(30mL)中,而后加入Boc2O(413mg)。氮气保护,升至60度加热搅拌。TLC检测反应,上一步的的原料和产物上Boc可以在TLC上分开。而后用DCM/H2O萃取,无水硫酸钠干燥,得目标产物20mg灰色固体。
步骤11-6:
以化合物11-5(20mg,0.035mmol)和5-5(15mg)为原料,按照步骤8-4的合成方法,制得淡黄色固体20mg。
步骤11-7:
向15mL Schlenk管中加入11-6(93mg),DCM(2mL),滴加HCl-Dioxane(0.4mL)N2保护下室温,搅拌反应(黄色浑浊)。1h LC-MS检测反应完全。直接油泵拉干得83mg,黄色固体。
步骤11-8:
以化合物11-7(83mg)为原料,按照步骤8-6的合成方法,制得34mg淡黄色固体。ESI(APCI):734[M+H]+.1H NMR(400MHz,DMSO-d6)δ9.88(s,1H),9.12-9.00(m,2H),8.53(s,1H),8.39(s,1H),8.31-8.19(m,2H),7.73(q,J=7.0,6.4Hz,2H),7.56(t,J=8.0Hz,1H),7.38(d,J=5.8Hz,1H),7.11(d,J=7.7Hz,1H),5.00(s,1H),4.61(s,1H),4.43(d,J=27.4Hz,1H),3.30-3.14(m,2H),2.71-2.58(m,3H),2.39(dd,J=9.4,4.3Hz,0H),2.07-1.75(m,2H).
实施例12化合物012的合成
步骤12-1:
将化合物11-3(1g,2.35mmol)溶于THF(30mL)中,而后加入碳酸钾(975mg,7.06mmol)和溴乙酸乙酯(393mg,2.35mmol),于60度加热搅拌过夜,LC-MS检测反应。反应完全后,用DCM/H2O萃取,无水硫酸钠干燥,柱层析,得600mg灰棕色固体。
步骤12-2:
以化合物12-1(200mg)和5-5(280mg)为原料,按照步骤8-4的合成方法,制得淡黄色固体52mg。
步骤12-3:
以化合物11-7(52mg)为原料,按照步骤8-6的合成方法,制得21mg淡黄色固体。ESI(APCI):720[M+H]+.1H NMR(400MHz,DMSO-d6)δ9.89(s,1H),9.12-8.98(m,2H),8.54(d,J=2.0Hz,1H),8.41(s,1H),8.29-8.17(m,2H),7.79-7.68(m,2H),7.56(t,J=8.0Hz,1H),7.38(d,J=5.8Hz,1H),7.12(dd,J=7.6,1.5Hz,1H),5.01(dd,J=8.1,3.5Hz,1H),4.62(s,1H),3.96(d,J=6.2Hz,2H),3.29(s,2H),2.69-2.52(m,1H),2.47(s,2H),1.90(d,J=55.7Hz,2H).
实施例13化合物013的合成
步骤13-1:
向100mL圆底烧瓶中加入12-1(150mg,0.3159mmol),MeI(54mg,0.3791mmol),K2CO3(87mg,0.6318mmol),THF(30mL),N2保护下室温搅拌反应过夜(深黄色澄清),LC-MS检测反应。反应完全后,旋干THF,DCM(20mL*2)萃取,柱层析,得灰色固体76mg。
步骤13-2:
以化合物13-1(50mg)和5-5(52mg)为原料,按照步骤8-4的合成方法,制得淡黄色固体70mg。
步骤13-3:
以化合物13-2(62mg)为原料,按照步骤8-6的合成方法,制得20.5mg淡黄色固体。ESI(APCI):734[M+H]+.1H NMR(400MHz,DMSO-d6)δ9.89(s,1H),9.19-8.92(m,2H),8.54(s,1H),8.37(s,1H),8.33-8.12(m,2H),7.88-7.63(m,2H),7.56(t,J=8.0Hz,1H),7.38(d,J=5.9Hz,1H),7.13(dd,J=7.6,1.5Hz,1H),5.47(s,2H),5.12(s,1H),4.64(d,J=17.9Hz,2H),4.43(d,J=26.4Hz,1H),3.28(s,2H),3.25-3.15(m,2H),2.68(s,2H),2.08-1.90(m,2H),1.83(s,2H).
实施例14化合物014的合成
步骤14-1:
将化合物14-1(5g,0.0231mol,WO2019148036),乙烯基硼酸频哪酯(7.7mL,0.0463mmol),磷酸钾(14.7g,0.0693mol),Pd(OAc)2(0.52g,0.0023mol)和SPhos(1.89g,0.0046mol)依次加入装有1,4-dioxane/H2O(4∶1,50mL)的单口瓶中,氮气保护,于油浴85℃下搅拌过夜,TLC检测反应。当原料消失后,将反应液悬干,柱层析,得淡黄色固体2.4g。
步骤14-2:
将化合物14-2(1.4g,9mmol)悬浮于原甲酸三乙酯(20mL)中,于油浴145℃下回流6小时,TLC检测反应。当原料消失后,将反应液冷却,加入正庚烷搅洗10分钟,过滤,重复以上操作2次,过滤,烘干得淡黄色固体1.35g。
步骤14-3:
将化合物14-3(1.25g,7.22mmol)和DIPEA(1.4g,10.83mmol)加入甲苯(75mL)中,升至100度搅拌,而后加入三氯氧磷(1.1g,7.22mmol),将反应液于油浴100℃下搅拌1.5小时,TLC检测反应。当原料消失后,将反应液慢慢倒入冰块中(50g)搅拌20分钟,过滤,分液,用卤水洗涤2次,有机层无硫酸酸钠干燥,悬干,得灰绿色固体820mg。
步骤14-4:
将化合物14-4(820mg,4.44mmol),3-溴-2-甲基苯胺(908mg,4.88mmol)和TsOH.H2O(844mg,4.44mmol)加入异丙醇(20mL)中,升至85度回流搅拌过夜,TLC检测反应。当原料消失后,悬干溶剂,DCM/H2O萃取,合并有机层,有机层用饱和碳酸氢钠溶液洗涤,无水硫酸钠干燥有机层,柱层析,得黄色固体600mg。
步骤14-5:
将化合物14-5(600mg,1.76mmol),NMO(412mg,3.52mmol),K2OsO4·2H2O(65mg,0.176mmol)和NaIO4(2.63g,12.31mmol)溶于THF/H2O(10mL/5mL)中,于室温下搅拌3小时,TLC检测反应。当原料消失后,过滤,乙酸乙酯淋洗固体。取滤液,用10%的硫代硫酸钠和卤水洗涤,无水硫酸钠干燥,浓缩,得淡黄色油状物600mg,直接用于下一步反应。
步骤14-6:
将化合物14-6(600mg,1.75mmol),(R)-3-羟基吡咯盐酸盐(949mg)和DIPEA(678mg,5.24mmol)溶于DCM(20mL)中,于室温下搅拌1小时。然后将NaBH(OAc)3(741mg,3.5mmol)加入上述反应液中,室温搅拌过夜。当原料消失后,滴加饱和碳酸氢钠溶液淬灭反应,乙酸乙酯/水萃取,合并有机层,无水硫酸钠干燥,柱层析,得淡黄色固体350mg。
步骤14-7:
以化合物14-7(350mg)为原料,按照步骤8-3的合成方法,得淡黄色固体300mg。
步骤14-8:
以化合物14-8(200mg)和7-2(180mg)为原料,按照步骤8-4的合成方法,得淡黄色固体300mg。MS(APCI):721[M+H]+
实施例15化合物015的合成
步骤15-1:
以化合物15-1(200mg)为原料,按照步骤8-3的合成方法,得淡黄色固体150mg。
步骤15-2:
以化合物15-1(100mg,WO2019191707)和7-2(120mg)为原料,按照步骤8-4的合成方法,制得淡黄色固体21mg。MS(APCI):736[M+H]+.
实施例16化合物016的合成
步骤16-1:
以化合物16-1(200mg)为原料,按照步骤8-3的合成方法,得淡黄色固体100mg。
步骤16-2:
以化合物16-1(50mg,WO2019191707)和7-2(56mg)为原料,按照步骤8-4的合成方法,制得淡黄色固体25mg。MS(APCI):771[M+H]+.
按照化合物001-016的合成方法,以相应的原料和试剂合成了下列表中的化合物:
/>
/>
实施例280化合物280的合成
步骤280-1:
以化合物1-3(2.4g)为原料,按照步骤1-2的合成方法,得到淡黄色固体3.1g。MS-APCI:334[M+H]+.
步骤280-2:
以化合物280-1(500mg)为原料,按照步骤1-3的合成方法,得到淡黄色固体200mg。MS-APCI:654[M+H]+.
步骤280-3:
以化合物280-2(200mg)为原料,按照步骤1-4的合成方法,得到淡黄色固体60mg。MS-APCI:753[M+H]+.
步骤280-4:
以化合物280-3(60mg)为原料,按照步骤1-5的合成方法,得到淡黄色固体16mg。MS-APCI:654[M+H]+.
1H NMR(400MHz,DMSO-d6)δ9.34(s,1H),9.00(s,1H),8.46(s,1H),8.34(d,J=8.0Hz,1H),8.08(d,J=8.0Hz,1H),7.77(d,J=8.0Hz,1H),7.44(t,J=8.0Hz,1H),7.35-7.25(m,3H),7.19(d,J=8.0Hz,1H),6.91(d,J=8.0Hz,1H),6.52(m,1H),4.49-4.39(m,3H),3.37-2.83(m,3H),2.66-2.28(m,2H),2.21(s,3H),2.18-2.06(m,1H),2.06(s,3H),1.96-1.58(m,5H),1.43(m,1H).
实施例281化合物280的合成
步骤281-1:
以化合物3-12(5g)为原料,按照步骤4-1的合成方法,得到淡黄色固体3g。MS-APCI:320[M+H]+.
步骤281-2:
以化合物280-1(1g)为原料,按照步骤1-3的合成方法,得到淡黄色固体400mg。MS-APCI:640[M+H]+.
步骤281-3:
以化合物280-2(400mg)为原料,按照步骤1-4的合成方法,得到淡黄色固体10mg。MS-APCI:739[M+H]+.
步骤281-4:
以化合物280-3(100mg)为原料,按照步骤1-5的合成方法,得到淡黄色固体36mg。MS-APCI:725[M+H]
生物测试
实施例A:PD-1/PD-L1均相时间分辨荧光(HTRF)结合测定
测定在标准黑色384孔聚苯乙烯板中进行,终体积为20μL。首先将抑制剂用DMSO连续稀释后加入板孔中,再加入其他反应组分。测定中DMSO的最终浓度为1%。测定是在25℃下含有0.05%Tween-20和0.1%BSA的PBS缓冲液(pH7.4)中进行的。在C端带有His标记的重组人PD-L1蛋白(19-238)购自AcroBiosystems公司(PD1-H5229)。在C端带有Fc标记的重组人PD-1蛋白(25-167)也购自AcroBiosystems公司(PD1-H5257)。将PD-L1和PD-1蛋白在测定缓冲液中稀释然后提取0.1μl溶液加入到板孔中。离心平板并将蛋白质与抑制剂预孵育40分钟。孵育后加入0.1μl HTRF检测缓冲液含有铕封闭标记的抗人IgG(PerkinElmer-AD0212)Fc专属的和抗His的-别藻蓝蛋白(APC,PerkinElmer-AD0059H)缀合的抗体。离心后,将孔板在25℃下孵育60分钟。置于PHERAstar FS读板器中读取数据(665nm/620nm比率)。测定中的最终浓度为~3nM PD1、10nM PD-L1、1nM铕抗人IgG和20nM抗-His-别藻蓝蛋白。使用GraphPad Prism5.0软件拟合活性数据得出抑制剂的IC50值。
实施例中举例说明的化合物IC50值以下列方式表示:IC50:+:≤10nM;++:10nM~100nM;+++:>100nM。
使用实施例A中描述的PD-1/PD-L1均相时间分辨荧光(HTRF)结合测定获得的实施例化合物的数据表明,所测试的本发明化合物的IC50绝大部分小于10nm,部分化合物(约25%)甚至小于1nM,部分优选化合物的活性测试数据提供于表1中。
/>
在本发明提及的所有文献都在本申请中引用作为参考,就如同每一篇文献被单独引用作为参考那样。此外应理解,在阅读了本发明的上述讲授内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
Claims (18)
1.一种如下式I所示的化合物,或其药学上可接受的盐:
其中,所述的为选自下组的结构:
n为0、1、2、3或4;
m、p和各自独立地选自0、1、2、3,4;
各自独立地为/>
所述的选自下组:/>
或为/>其中,X7、X8和X10各自独立地为CR;X6为N;X9和X11各自独立地选自下组:N、CR;各个R各自独立地选自下组:H、-CN、三氟甲基、-CHF2、-OCF3、-OCHF2、磺酰氨基、硝基、羟基、卤素、取代或未取代的C1-C10烷基;
R6选自下组:取代或未取代的-(C1-C6亚烷基)-NH-(C1-C6烷基)、
L1选自下组:化学键、取代或未取代的-NH-;
R2、R3和R5各自独立地选自下组:H、-CN、三氟甲基、-CHF2、-OCF3、-OCHF2、磺酰氨基、硝基、羟基、卤素、C1-C10烷基、C1-C6烷氧基、C3-C8环烷基、羟基、C1-C6胺基、羧基R1选自下组:H、-CN、三氟甲基、-CHF2、-OCF3、-OCHF2、磺酰氨基、硝基、羟基、卤素、C1-C10烷基、C1-C6烷氧基、C3-C8环烷基、羟基、C1-C6胺基、羧基、取代或未取代的C1-C6胺基、取代或未取代的-(C1-C6亚烷基)-NH-(C1-C6亚烷基)-(具有1-3个选自N、S和O的杂原子的5-10元杂环基)、取代或未取代的
R4选自下组:NRdRe、取代或未取代的C1-C6胺基、取代或未取代的-(C1-C6亚烷基)-NH-(C1-C6烷基),其中,所述R4的取代指被选自下组的一个或多个取代基所取代:卤素、-CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3、氧代(=O)、-CN、羟基、氨基、C1-C6烷胺基、羧基、-NHAc、未取代或被一个或多个取代基取代的选自下组的基团:C1-C6烷基、C1-C6烷氧基、C3-C8环烷基;其中,所述的取代基选自下组:卤素、羟基、羧基、氧基、氰基、C1-C6烷氧基、C1-C6烷胺基;
其中,Rb和Rc各自独立地选自下组:H、取代或取代的C1-C8烷基;或所述的Rb和Rc与相邻的N原子共同构成取代或未取代的具有1-3个选自N、S和O的杂原子的3-10元杂环基,或所述的Rb和Rc与相邻的N原子共同构成取代或未取代的4-10元内酰胺,所述取代基选自下组:羟基、羧基、巯基、氨基、F、Cl;
Rd、Re各自独立地选自下组:H、取代或未取代的C1-C6烷基、取代或未取代的C3-C10环烷基;或Rd和Re共同形成取代或未取代的具有1-3个选自N、S和O的杂原子的4-10元杂环基;
Rb、Rc和Rd的碳原子上的氢均可各自独立地被氘替换;
所述的“取代”是指被选自下组的一个或多个取代基所取代:卤素、-CH2Cl、-CHCl2、-CCl3、-CH2F、-CHF2、-CF3、氧代、-CN、羟基、氨基、C1-C6烷胺基、羧基、-NHAc、未取代或被一个或多个取代基取代C1-C6烷基或C1-C6烷氧基;其中,所述的取代基选自下组:卤素、羟基、羧基、氧基、氰基、C1-C6烷氧基、C1-C6烷胺基;
上述各式中,任一所述杂原子选自下组:B、P、N、S和O;
且所述的化合物不为选自下组的结构:
/>
2.如权利要求1所述的化合物,其特征在于,所述的具有如下式所示的结构:
其中,
X6、X7、X8、X9、X10和X11各自独立地选自下组:N、CR;
R6选自下组:取代或未取代的-(C1-C6亚烷基)-NH-(C1-C6烷基)、
3.如权利要求1所述的化合物,或其药学上可接受的盐,其特征在于,所述的具有如下式所示的结构:/>其中,所述的环的成键位置可以为N或C。
4.如权利要求1所述的化合物,或其药学上可接受的盐,其特征在于,所述的环具有如下式IV所示的取代基:/>
其中,w为1、2或3;m'为0、1、2、3,4;
所述的各个L4独立地选自下组:取代或未取代的C1-C4亚烷基、或NRf;其中,取代或未取代的C1-C4亚烷基上碳原子上的氢均可各自独立地被氘替换;前提条件是各个L4共同形成的结构是化学稳定的;
选自下组:取代或未取代的具有1-3个选自B、P、N、S和O的杂原子的3-10元杂环基;
各个R7各自独立地选自下组:取代或未取代的C1-C6烷基、-CN、羟基、氨基、羧基;其中,所述的取代基选自下组:卤素、羟基、羧基、氰基、C1-C6烷氧基。
5.如权利要求4所述的化合物,或其药学上可接受的盐,其特征在于,所述的为或取代或未取代的5-8元含氮杂环基,或取代或未取代的5-10元环酰胺,其中,5-8元含氮杂环基取代或未取代的5-10元环酰胺基的成环碳原子上的氢均可各自独立被氘替换。
6.如权利要求1所述的化合物,其特征在于,所述的为选自下组的结构:
7.一种选自下组的化合物;
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
/>
8.一种如权利要求1所述的式I化合物的制备方法,其特征在于,所述的方法包括选自合成方案1、2或3所示的步骤:
合成方案1:
(a)以中间体II和III为原料,通过钯催化剂催化的Sonogashira偶联反应得到目标产物I-1;
合成方案2:
(a)以化合物II-1为原料,与硝化剂反应,形成中间体IV-1;
(b)以IV-1为原料,在还原条件下,发生还原反应,形成中间体IV-2;
(c)以IV-2和IV-3为原料,在碱性条件下,发生亲和取代反应得到酰胺中间体;而后在合适的脱水试剂下发生环化反应,得到中间体IV-4;
(d)以IV-4和IV-5为原料,在催化剂和配体的条件下,发生偶联反应,形成中间体I-2;
合成方案3:
(a)以V-1和V-2为原料,在催化剂和配体的条件下,发生偶联反应,形成中间体V-3;
(d)以IV-4和合适的硼源为原料,在催化剂和配体的条件下,发生偶联反应,形成中间体V-4;
(d)以V-4和IV-4为原料,在催化剂和配体的条件下,发生偶联反应,形成目标产物I-3;
上述各式中,为/>X6-X10、R1-R5、t、m、n的定义如前所述。
9.如权利要求8所述的方法,其特征在于,所述的中间体II-2的制备方法如下:
(a)以II-1为原料,在路易斯酸催化下,发生卤代反应,得到中间体II-2。
10.如权利要求8所述的方法,其特征在于,所述的中间体III的制备方法如下:
(a)以化合物III-1和III-2为原料,在钯催化剂和配体的条件下,发生偶联反应,得到中间体III-3;
(b)以III-3为原料,使用合适的试剂,移除硅基保护基,得到中间体III。
11.一种药物组合物,其特征在于,包含(1)如权利要求1-7任一所述的化合物或其药学上可接受的盐;(2)药学上可接受的载体。
12.如权利要求1-7任一所述的化合物或其药学上可接受的盐,或如权利要求11所述的药物组合物的用途,其特征在于,用于制备预防和/或治疗与PD-1/PD-L1的活性或表达量相关的疾病的药物组合物。
13.如权利要求12所述的用途,其特征在于,所述的药物组合物用于治疗选自下组的疾病:癌症、感染性疾病、自身免疫性疾病。
14.如权利要求12所述的用途,其特征在于,所述的癌症选自下组:胰腺癌,膀胱癌,结肠直肠癌,乳腺癌,前列腺癌,肾癌,肝细胞癌,卵巢癌,宫颈癌,胃癌,食道癌,黑色素瘤,神经内分泌癌,脑癌,骨癌,软组织肉瘤,非小细胞肺癌癌症,小细胞肺癌、结肠癌、皮肤癌、肺癌、泌尿系肿瘤、血液肿瘤、胶质瘤、淋巴瘤、脑瘤、头颈癌。
15.如权利要求12所述的用途,其特征在于,所述的癌症选自下组:肺癌,中枢神经系统癌,消化系统肿瘤、生殖系统肿瘤、神经系统肿瘤。
16.如权利要求12所述的用途,其特征在于,所述的感染性疾病选自细菌感染、病毒感染。
17.如权利要求12所述的用途,其特征在于,所述的自身免疫性疾病选自器官特异性自身免疫病、系统性自身免疫病。
18.如权利要求12所述的用途,其特征在于,所述的药物组合物还包括至少一种选自下组的治疗剂:纳武单抗,派姆单抗,atezolizumab,或伊匹单抗。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019108489269 | 2019-09-09 | ||
CN201910848926.9A CN112457308B (zh) | 2019-09-09 | 2019-09-09 | 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用 |
PCT/CN2020/114253 WO2021047547A1 (zh) | 2019-09-09 | 2020-09-09 | 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114364676A CN114364676A (zh) | 2022-04-15 |
CN114364676B true CN114364676B (zh) | 2024-02-02 |
Family
ID=74807433
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910848926.9A Active CN112457308B (zh) | 2019-09-09 | 2019-09-09 | 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用 |
CN202080063269.8A Active CN114364676B (zh) | 2019-09-09 | 2020-09-09 | 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910848926.9A Active CN112457308B (zh) | 2019-09-09 | 2019-09-09 | 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220372031A1 (zh) |
EP (1) | EP4029865A4 (zh) |
JP (1) | JP2022547201A (zh) |
KR (1) | KR20220062053A (zh) |
CN (2) | CN112457308B (zh) |
AU (1) | AU2020346936B2 (zh) |
CA (1) | CA3153702A1 (zh) |
MX (1) | MX2022002839A (zh) |
WO (1) | WO2021047547A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023526548A (ja) * | 2020-05-22 | 2023-06-21 | シャンハイ ロングウッド バイオファルマシューティカルズ カンパニー リミテッド | 新規三環芳香族複素環化合物、ならびにその調製方法、医薬組成物および適用 |
CN113121464B (zh) * | 2021-04-21 | 2023-02-24 | 药康众拓(江苏)医药科技有限公司 | 五元杂环取代的联苯类化合物及其制备方法和用途 |
WO2022257833A1 (zh) * | 2021-06-07 | 2022-12-15 | 上海海雁医药科技有限公司 | 取代的苯基丙烯基吡啶类衍生物中间体及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3429877A (en) * | 1965-02-15 | 1969-02-25 | Ciba Ltd | Azole compounds |
US3859350A (en) * | 1971-08-13 | 1975-01-07 | Hoechst Ag | Benzofurane derivatives, process for their preparation and their use as optical brighteners |
US3892807A (en) * | 1972-12-18 | 1975-07-01 | Hoechst Ag | Aromatic azomethines |
CN101160307A (zh) * | 2005-02-17 | 2008-04-09 | Amr科技公司 | 用于治疗cinv和ibs-d的苯并噁唑甲酰胺 |
WO2018195321A1 (en) * | 2017-04-20 | 2018-10-25 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
CN109689640A (zh) * | 2016-07-08 | 2019-04-26 | 百时美施贵宝公司 | 可用作免疫调节剂的化合物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0102687D0 (en) * | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
DE10232572A1 (de) * | 2002-07-18 | 2004-02-05 | Bayer Ag | Neue 2,5-disubstituierte Pyrimidinderivate |
US8148363B2 (en) * | 2008-05-19 | 2012-04-03 | Schering Corporation | Heterocyclic compounds as factor IXA inhibitors |
DE102009033208A1 (de) * | 2009-07-15 | 2011-01-20 | Merck Patent Gmbh | Aminopyridinderivate |
CA2809836C (en) | 2010-09-01 | 2019-01-15 | Gilead Connecticut, Inc. | Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase |
FR3037956B1 (fr) | 2015-06-23 | 2017-08-04 | Servier Lab | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2017059135A1 (en) | 2015-10-02 | 2017-04-06 | Abide Therapeutics, Inc. | Lp-pla2 inhibitors |
CA3029857C (en) | 2016-07-05 | 2023-07-04 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof |
ES2934230T3 (es) * | 2016-12-22 | 2023-02-20 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores |
CA3047991A1 (en) * | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
JP2020505457A (ja) | 2017-01-23 | 2020-02-20 | ユニヴァーシティ オブ ハワイUniversity Of Hawaii | 2−アリールスルホンアミド−N−アリールアセトアミド誘導体化Stat3 |
CR20200355A (es) | 2018-01-26 | 2021-02-22 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
FI3774791T3 (fi) | 2018-03-30 | 2023-03-21 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
-
2019
- 2019-09-09 CN CN201910848926.9A patent/CN112457308B/zh active Active
-
2020
- 2020-09-09 US US17/641,162 patent/US20220372031A1/en active Pending
- 2020-09-09 MX MX2022002839A patent/MX2022002839A/es unknown
- 2020-09-09 KR KR1020227011833A patent/KR20220062053A/ko not_active Application Discontinuation
- 2020-09-09 EP EP20862539.2A patent/EP4029865A4/en active Pending
- 2020-09-09 CA CA3153702A patent/CA3153702A1/en active Pending
- 2020-09-09 CN CN202080063269.8A patent/CN114364676B/zh active Active
- 2020-09-09 WO PCT/CN2020/114253 patent/WO2021047547A1/zh unknown
- 2020-09-09 AU AU2020346936A patent/AU2020346936B2/en active Active
- 2020-09-09 JP JP2022515642A patent/JP2022547201A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3429877A (en) * | 1965-02-15 | 1969-02-25 | Ciba Ltd | Azole compounds |
US3859350A (en) * | 1971-08-13 | 1975-01-07 | Hoechst Ag | Benzofurane derivatives, process for their preparation and their use as optical brighteners |
US3892807A (en) * | 1972-12-18 | 1975-07-01 | Hoechst Ag | Aromatic azomethines |
CN101160307A (zh) * | 2005-02-17 | 2008-04-09 | Amr科技公司 | 用于治疗cinv和ibs-d的苯并噁唑甲酰胺 |
CN109689640A (zh) * | 2016-07-08 | 2019-04-26 | 百时美施贵宝公司 | 可用作免疫调节剂的化合物 |
WO2018195321A1 (en) * | 2017-04-20 | 2018-10-25 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
Non-Patent Citations (2)
Title |
---|
Highly Potent Naphthofuran-Based Retinoic Acid Receptor Agonists;Efren Perez Santin 等;《ChemMedChem》;第4卷(第5期);第780-791页 * |
Synthesis of Naphthalenes and 2-Naphthols by the Electrophilic Cyclization of Alkynes;Xiaoxia Zhang 等;《J. Org. Chem.》;第71卷(第1期);第242页Scheme 3 * |
Also Published As
Publication number | Publication date |
---|---|
CN112457308A (zh) | 2021-03-09 |
MX2022002839A (es) | 2022-04-26 |
JP2022547201A (ja) | 2022-11-10 |
WO2021047547A1 (zh) | 2021-03-18 |
CA3153702A1 (en) | 2021-03-18 |
KR20220062053A (ko) | 2022-05-13 |
EP4029865A4 (en) | 2024-01-10 |
AU2020346936A1 (en) | 2022-04-21 |
CN112457308B (zh) | 2024-01-02 |
CN114364676A (zh) | 2022-04-15 |
EP4029865A1 (en) | 2022-07-20 |
AU2020346936B2 (en) | 2024-03-14 |
US20220372031A1 (en) | 2022-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111039942B (zh) | 含氮杂环类化合物,及其制备方法、药物组合物和应用 | |
CN114364676B (zh) | 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用 | |
CN113045565A (zh) | 新型K-Ras G12C抑制剂 | |
CN115279760A (zh) | 新型hpk1抑制剂及其制备方法和应用 | |
CN116390728B (zh) | 喹唑啉衍生物及其制备方法和用途 | |
CN113637013A (zh) | 联芳环链接芳杂环衍生物作为免疫调节剂的制备及其应用 | |
CN114364673A (zh) | 含三环结构的芳香杂环化合物,及其制备方法和应用 | |
CN113045569B (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
CN112457329B (zh) | 芳香杂环衍生物作为免疫调节剂的制备及其应用 | |
WO2020057669A1 (zh) | 一类具有激酶抑制活性的芳香杂环类化合物 | |
CN114364685A (zh) | 含氮杂环类化合物,及其制备方法、药物组合物和应用 | |
CN113166109B (zh) | 氨基吡啶类化合物及其制备方法和用途 | |
CN111978325B (zh) | 咪唑并哒嗪类mnk1/mnk2激酶抑制剂及其制备方法和应用 | |
EP4159736A1 (en) | Novel tricyclic aromatic heterocyclic compound and preparation method therefor, pharmaceutical composition and use thereof | |
CN117658915A (zh) | 三并环类化合物及其制备方法和应用 | |
CN115746026A (zh) | 吡咯并嘧啶类衍生物及其制备方法和应用 | |
CN116969976A (zh) | 去泛素化酶抑制剂及其应用 | |
CN117105919A (zh) | 一种靶向抗肿瘤药物及其在制备药物中的用途 | |
CN117800976A (zh) | 一类含氮杂环类化合物、制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40067795 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |